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Abstract 
Malarial infection in naïve individuals induces a robust innate immune response, but 
our understanding of the mechanisms by which the innate immune system recognizes 
malaria and regulates its response remain incomplete. Our group previously showed 
that stimulation of macrophages with Plasmodium falciparum genomic DNA (gDNA) 
and AT-rich oligodeoxynucleotides (ODNs) derived from this gDNA induces the 
production of type I interferons (IFN-I) through a STING/TBK1/IRF3-dependent 
pathway; however, the identity of the upstream cytosolic DNA receptor remained 
elusive. Here, we demonstrate that this IFN-I response is dependent on cyclic GMP-
AMP synthase (cGAS). cGAS produced the cyclic dinucleotide 2’3’-cGAMP in 
response to P. falciparum gDNA and AT-rich ODNs, inducing IRF3 phosphorylation 
and IFNB transcription. In the recently described model of innate immune memory, 
an initial stimulus primes the innate immune system to either hyperrespond (termed 
“training”) or hyporespond (“tolerance”) to subsequent immune challenge. Previous 
work in mice and humans demonstrated that infection with malaria can both serve as 
a priming stimulus and promote tolerance to subsequent infection. In this study, we 
demonstrate that initial stimulation with P. falciparum-infected red blood cells 
(iRBCs) or the malaria crystal hemozoin (Hz) induced human adherent peripheral 
blood mononuclear cells (PBMCs) to hyperrespond to subsequent Toll-like receptor 
(TLR) challenge. This hyperresponsiveness correlated with increased H3K4me3 at 
important immunometabolic promoters, and these epigenetic modifications were also 
seen in monocytes from Kenyan children naturally infected with malaria.  However, 
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the use of epigenetic and metabolic inhibitors indicated that malaria-induced trained 
immunity may occur via previously unrecognized mechanism(s). 
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Chapter I: Introduction 
Malaria: A primer 
Malaria, along with HIV/AIDS and tuberculosis, remains one of the world’s most 
pressing infectious disease-related global health issues. According to the World Health 
Organization’s most recent World Malaria Report, although the malaria incidence rate 
has decreased by over 40% and 17 nations have eradicated malaria since the year 2000, 
there were still an estimated 212 million new cases of malaria worldwide in 2015, with 
nine in ten of those occurring in Africa (1). These cases resulted in over 400,000 deaths, 
92% of which occurred in Africa and the majority in children under the age of five (1). 
Malarial disease in humans is primarily caused by infection with one of four parasite 
species from the protozoan genus Plasmodium: Plasmodium falciparum, Plasmodium 
vivax, Plasmodium ovale, and Plasmodium malariae. P. falciparum infection is the most 
common infection worldwide and is responsible for 99% of fatalities due to malaria (1). 
Infection with P. vivax has the second highest prevalence, and although the WHO 
estimates that only 4% of new malaria infections in 2015 were due to P. vivax, more than 
40% of malarial infections outside of Africa were due to P. vivax, primarily in southern 
and southeast Asia, islands of the western Pacific, and central and South America (1). 
The malarial life cycle is complex, involving development in both human and 
mosquito hosts. For simplicity, the stages of human infection are briefly summarized 
here. Infection is transmitted when Plasmodium sporozoites are injected into the skin 
through the bite of an infected Anopheles mosquito. The sporozoite then invades the 
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vasculature and travels to the liver, where it invades a hepatocyte and begins to divide 
asexually. After several cycles of asexual reproduction during this liver stage of infection, 
the hepatocyte ruptures, releasing the daughter malaria parasites—now called 
merozoites—into the bloodstream. These merozoites then each infect a red blood cell 
(RBC), where they continue to replicate asexually. During this blood stage of replication, 
which takes 48-72 hours depending on the species of parasite (2), the merozoites 
develops sequentially into a ring form, then a trophozoite, which then reproduces 
asexually to produce many daughter merozoites. The resulting schizont—the RBC 
containing the daughter merozoites—ruptures, releasing these merozoites into the 
bloodstream to each infect a new RBC. In P. vivax and P. ovale, some of the parasites 
reinfect the liver, where they remain dormant as hypnozoites. These hypozoites, through 
reactivation and escape from the hepatocyte, can then cause relapse after clearance of the 
original blood stage infection. For all species of malarial parasites, the infection is 
propagated when an Anopheles mosquito takes a blood meal from an infected individual 
which includes both male and female gametocytes, which can also develop from blood 
stage parasites. The gametocytes combine sexually in the mosquito, where through 
further developmental processes in the mosquito [thoroughly reviewed in (3)], 
sporozoites mature and migrate to the mosquito salivary gland for infection of a new 
human host. 
Human malarial disease is believed to be the result of blood stage infection. 
General symptoms of uncomplicated blood stage infection include fevers, chills, rigors, 
malaise, and other flu-like symptoms. The majority of malarial infections remain 
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uncomplicated; however, some infections—most commonly in children under the age of 
five or naïve individuals—become severe and potentially life-threatening. Symptoms of 
severe malaria include, but are not limited to, respiratory distress, convulsions, severe 
anemia, loss of consciousness, and circulatory collapse (4). The majority of severe 
malaria cases fall into one of three groups: malaria with metabolic 
disturbances/respiratory distress, severe malarial anemia (SMA), and cerebral malaria 
(CM) (5, 6).  
Of these three, CM, which affects over 575,000 children in Sub-Saharan Africa 
annually (7), is arguably the most dangerous, as it can progress rapidly and has an 
ultimate fatality rate of 15-20% (4). CM is defined by the World Health Organization as a 
coma lasting longer than one hour after the cessation of convulsions that is associated 
with P. falciparum parasitemia and cannot be explained by any other etiology (4). Based 
on early postmortem anatomical and histological specimens, sequestration of P. 
falciparum infected red blood cells (iRBCs) resulting in obstruction of the cerebral 
microvasculature was determined to be the primary mechanism behind CM pathogenesis 
(8), and it has also been implicated in other forms of severe malarial illness (6). While 
iRBC sequestration is still believed to be one of the main drivers of CM, further research 
indicates that CM pathogenesis is more complex. A postmortem study of 31 patients 
diagnosed clinically with CM found that 18 of the patients had cerebral histopathology 
typical of CM—sequestered iRBCs, parenchymal hemorrhage, and leukocyte 
accumulation—while six had sequestration only and seven had no iRBC sequestration at 
all (9). Conversely, cerebral iRBC sequestration can also be seen in malaria patients who 
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do not have clinical symptoms of CM (10). Breakdown of the blood-brain barrier (BBB) 
appears to be important in CM pathogenesis, and mononuclear cells have been identified 
at these lesions (11), suggesting a potential role for the immune system in CM 
pathogenesis.  
 As mentioned previously, immunologically naïve individuals are most at risk for 
severe malarial disease. However, for individuals in endemic area, the risk of severe 
malaria drops precipitously with age as the individual is exposed more frequently to the 
parasite. It has been estimated that the risk of severe malaria—excluding cerebral 
malaria—largely disappears after only one or two infections (12). Although it is less 
likely that children over the age of five will contract severe malaria in endemic areas, 
they are still at risk for uncomplicated malaria, with the flu-like symptoms discussed 
earlier (13). By the time individual reach the age of thirty, they are largely immune to 
clinical malaria (13). However, it is not uncommon for adults and older children in 
endemic areas to have asymptomatic parasitemia; that is, they have detectable levels of 
parasite in the bloodstream—crucially, at high enough levels to transmit the parasite 
through a mosquito blood meal—but remain afebrile and appear healthy. This 
phenomenon of malarial tolerance will be explored later in this Chapter. But first, we 
need to introduce the immune system, with special focus on innate immunity. 
 
Introduction to innate immunity 
The immune system is traditionally divided into two interconnected arms: the innate 
immune system and adaptive immune system. According to this paradigm, first 
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elucidated by Charles Janeway in his landmark 1989 Cold Spring Harbor Symposia on 
Quantitative Biology paper (14), the innate immune system is composed of cells that 
express a limited number of germline-encoded pattern recognition receptors (PRRs), 
which recognize pathogen-associated molecular patterns (PAMPs) found exclusively on 
infectious organisms and non-self cells. Triggering these PRRs on cells such as 
macrophages and dendritic cells indicates to the innate immune system that a pathogen 
has been encountered. The innate immune system responds in two main ways: it activates 
an inflammatory response primarily through the production of proinflammatory cytokines 
in an effort to contain the infection, and it also activates B and T cells of the adaptive 
immune system. These adaptive immune cells contain unique receptors that are the 
product of somatic recombination at the V(D)J locus. The wide variety of receptors that 
can be generated by this process provides the adaptive immune system with the ability to 
respond quite specifically, but first these cells must be activated. This activation of the 
adaptive immune system requires two signals from a cell of the innate immune system: 
presentation of a protein component of the pathogen, termed an antigen, on a major 
histocompatibility complex (MHC) expressed on the antigen-presenting cell (APC) 
surface, and expression of a co-stimulatory molecule. Activation of the adaptive immune 
system then produces a clonal response that is specific to the invading pathogen, leading 
to its eradication from the body. The maintenance of memory B and T cells also allows 
the adaptive immune system to respond more immediately if the pathogen is encountered 
at a later time point.  
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Janeway’s main contribution to this paradigm was the idea that “the 
immunologist’s dirty little secret”—his term for the dead bacteria-containing, immune-
stimulating adjuvants required to initiate an adaptive response—may do so by triggering 
these PRRs (14). Triggering of these PRRs would then cause the expression of co-
stimulatory molecules, so that the adaptive immune system would only be triggered in the 
presence of a non-self challenge. The first PRR was discovered a few years later, in 1996, 
when Jules Hoffman’s group demonstrated that the transmembrane protein Toll was 
required to protect Drosophilia melanogaster from fatal fungal infection (15). A year 
later, Janeway, along with his mentee Ruslan Medzhitov, demonstrated that the human 
version of Toll—later renamed Toll-like receptor (TLR) 4—activated the NF-kB 
pathway, led to the production of proinflammatory cytokines, and induced the expression 
of costimulatory molecules on the cell surface (16).  
These landmark studies helped to open the floodgates of innate immunity 
research, and in the 20 years since the publication of Medzhitov and Janeway’s work on 
human Toll, the list of PRRs involved in innate immune recognition and signaling has 
exploded. After Toll, multiple members of what became known as the TLR family were 
described. Most of the TLRs are located on the plasma membrane or in an endosomal 
compartment. The nucleic-acid recognizing TLRs, including double-stranded RNA-
sensing TLR3 (17), single-stranded RNA-sensing TLR7 and TLR8 (18), and CpG motif-
containing DNA-sensing TLR9 (19), recognize their ligands in and signal from an 
endosomal compartment. Additionally, homodimers of TLR12 or TLR11/12 
heterodimers, depending on the cell type, recognize a profilin protein from T. gondii  in 
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the endosome (20, 21), while uropathogenic Escherichia coli are recognized by TLR11 
alone (22). On the plasma membrane, TLR2 recognizes lipoproteins (23, 24) through the 
formation of heterodimers with TLR1 (25) or TLR6 (26). TLR2 also recognizes 
peptidoglycan (27) and GPI anchors from Toxoplasmosis gondii (28), while TLR4 is the 
receptor for lipopolysaccharide (LPS) (29) with CD14 and MD-2 functioning as co-
receptors (30). Bacterial flagellin is recognized by TLR5 (31). These TLRs, once they 
recognize their cognate PAMP (or damage-associated molecular pattern—DAMP), 
dimerize and initiate a signaling cascade that begins with one of a handful of adaptor 
proteins— myeloid differentiation primary response gene 88 (MYD88), myelin and 
lymphocyte protein (MAL), Toll/interleukin-1 receptor-domain-containing adapter-
inducing IFNβ (TRIF), and TRIF-related adaptor molecule (TRAM)—and ends with the 
activation of a specific combination of transcription factors, such as nuclear factor kappa-
light-chain-enhancer of activated B cells (NF-kB) or interferon regulatory factors (IRFs), 
depending on the TLR(s) stimulated (32). 
The TLR family was the first PRR family discovered and is perhaps one of the 
evolutionarily oldest PRR families—the sea urchin, for example, has gene sequences for 
222 TLRs in its genome (33)—but it is far from the only PRR family. The C-type lectin 
receptor (CLR) family of PRRs are also expressed on the plasma membrane. Primarily 
known for their ability to recognize carbohydrates in fungal cell walls, they also play a 
role in the immune response to a variety of other pathogens (34). The NOD-like receptor 
(NLR) family, named for the central nucleotide-binding oligomerization domain shared 
by all of its members, is a family of cytosolic receptors that plays multiple roles in 
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pathogen sensing and proinflammatory signaling (35), although they are arguably best 
known for their roles as inflammasome sensors, which are critical for activating caspase-
1 to cleave pro-IL-1b and pro-IL-18 into their active forms (36).  
Cytosolic nucleic acids represent a potent family of PAMPs and DAMPs, and 
there are two intracellular PRR families dedicated to recognizing them. The RIG-I-like 
receptor (RLR) family is a family of helicases best known for inducing type I interferon 
(IFN-I) expression after binding to various RNA species (37). The final major PRR 
family is united not by structural similarity but by functional similarity: the cytosolic 
DNA receptors. This family includes absent in melanoma 2 (AIM2), which binds to 
double-stranded DNA (dsDNA) through its HIN200 domain and activates an apoptosis-
associated speck-like protein containing a caspase-recruitment domain (ASC)-containing 
inflammasome complex (38, 39); IFI16, a fellow HIN-containing protein that has been 
proposed, along with its mouse ortholog p204, to form the AIM2-like receptor (ALR) 
family (40); RNA polymerase III, which detects poly(dA:dT) and synthesizes a special 
RNA species for detection by RIG-I (41); and cyclic GMP-AMP synthase (cGAS), which 
catalyzes the synthesis of 2’3’-cGAMP after binding directly to DNA, leading to IFN-I 
production in a stimulator of interferon genes (STING)-dependent manner (42-45). Now 
we will turn our attention to the PRRs, PAMPs, and pathogenesis inherent in the innate 
immune recognition of malaria. 
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The innate immune response to malaria 
As discussed earlier, uncomplicated malarial illness is characterized by fever, malaise, 
and other flu-like symptoms. These symptoms, the hallmarks of malarial disease, are 
believed to be the result of robust proinflammatory cytokine production induced by 
widespread innate immune activation. Multiple PRRs are involved in recognizing 
malarial parasites and PAMPs. TLR2 recognizes P. falciparum 
glycosylphosphatidylinositol (GPI) anchors by forming heterodimers with TLR1 or 
TLR6 in macrophages (46). TLR2 also appears to recognize sporozoites in the P. yoelii 
mouse malaria model (47). Injection of hemozoin (Hz) crystals—the end product of heme 
metabolism by the malaria parasite—into mice causes the recruitment of monocytes to 
the area of injection, as well as the production of IL-1β, IL-6, and multiple chemokines 
(48). Work performed by our group and collaborators demonstrated that TLR9 recognizes 
Hz crystals coated with Plasmodium genomic DNA (gDNA) in the phagolysosome (49). 
Originally, it was believed that Hz was directly recognized by TLR9 (50), but our group 
demonstrated that DNase treatment of these crystals completely abrogated Hz-induced 
TLR9 activation (49). In recent years, other laboratories have demonstrated that TLR9 
recognizes DNA/protein complexes from malaria parasites (51), and later work 
demonstrated that these DNA/protein complexes were actually parasite nucleosomes 
(52).  
Hz crystals can also destabilize the phagolysosome and allow Plasmodium DNA 
to access the cytosol, where it is recognized by the AIM2 inflammasome and is an 
important component for IL-1b production in malarial infection (53). Hz itself is able to 
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activate the NLRP3 inflammasome, leading to robust cleavage of pro-IL-1β into its active 
form (53). The NLRP12 inflammasome is also activated—as evidenced by the presence 
of NLRP12 containing inflammasome specks in patient peripheral blood—during natural 
malarial infection(54). An additional cytosolic DNA receptor senses AT-rich stem-loop 
structures in Plasmodium genomes and produces IFN-I in a manner independent of p204, 
RNA pol III, and TLR9, but dependent on the STING/TANK binding kinase-1 
(TBK1)/IRF3/IRF7 axis (55). Innate immunity in Plasmodium infection does benefit the 
host by limiting parasitemia, clearing infected red blood cells (iRBCs), and assisting in 
the activation of adaptive immunity (56); however, innate immune activation is not 
without drawbacks.  
The proinflammatory cytokinemia resulting from infection with malaria has been 
well-defined, and even implicated in the development of severe pathology like cerebral 
malaria (57). A landmark 1989 study in the New England Journal of Medicine reported 
that serum tumor necrosis factor-α (TNFα) were higher in children who died of severe 
malaria than those that survived severe malaria, and that mortality rate was positively 
correlated with serum TNFα (58). Additionally, they found that TNFα levels were 
significantly higher in patients with parasite burdens greater than 106 trophozoites/µl than 
patients with parasite levels below this (58). In another study comparing serum cytokine 
levels between patients with severe malaria, uncomplicated malaria, and healthy controls 
with no parasites on blood smear (which does not rule out asymptomatic, submicroscopic 
infection), interleukin (IL)-6 and IL-10 levels were highest in patients with CM, 
significantly higher in severe malaria patients than uncomplicated malaria patients, and 
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these levels were higher in uncomplicated malaria patients than healthy controls, 
although surprisingly IL-6 levels were significantly lower in patients with 5x105 
parasites/µl than patients with higher parasite burdens (59). TNFα and IL-12 levels were 
significantly higher in severe malaria patients than healthy controls, while there were no 
significant differences between the groups for IL-1b or IL-8 (59).  
Despite many studies examining the effects of the immune system on CM 
pathogenesis (57, 60) a definitive role for immune cells and the cytokines they produce 
has yet to be determined. Since human studies of CM are largely limited to analysis of 
peripheral blood and postmortem tissue samples, interventional studies to determine the 
causative agent(s) of CM pathogenesis are restricted to animal models of CM. Using 
mouse models of malaria also allows for the determination of definite roles for various 
innate immune components in pathogenesis, but these models may not completely 
correspond to human disease.  
The Plasmodium berghei ANKA (PbA)-induced murine experimental cerebral 
malaria (ECM) model mimics many of the symptoms—including convulsions, seizures 
and coma—and histopathological changes of human CM (57). In this model, which 
involves infection of C57BL/6 mice with either PbA liver-stage forms called sporozoites 
or PbA iRBCs, multiple immune cell types and cytokines have been identified as 
essential for ECM pathogenesis. Conventional dendritic cells (cDCs), primarily CD8+ 
cDCs (61, 62), phagocytose iRBCs in the spleen and cross-present parasite antigens to 
CD8+ T cells, which are activated to a cytotoxic phenotype in a largely parasite antigen-
specific manner (63). These activated CD8+ T cells also express the chemokine receptor 
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CXCR3, which is required for effective trafficking to the brain (64). Once in the brain, 
activated CD8+ T cells recognize their cognate antigen cross-presented in the cerebral 
microvasculature (65) and damage the BBB—thus inducing ECM—in a perforin- and 
granzyme B-dependent manner (66, 67). 
Both CD4+ T cells and CD8+ T cells are required for ECM pathogenesis (68). 
Depletion of CD4+ T cells just before onset of ECM symptoms is not protective; 
however, depletion of CD8+ T cells at the same time point confers ECM resistance, 
indicating that CD8+ T cells are the primary cellular effectors in ECM (69). Although 
IFNγ has long been known to be necessary for the development of ECM (70), recent 
work showed that IFNγ expression by CD4+ T cells was sufficient to make previously 
resistant IFNγ-/- mice susceptible to ECM, and CD4+ T cell-derived IFNγ was important 
for CD8+ T cell trafficking to the brain (71). In addition to IFNγ, multiple recent studies 
have shown that type I interferons are also essential for ECM pathogenesis (55, 72-74). 
Interferons were so-named because of their ability to interfere with viral 
replication (75). Interferons can be divided into two classes: type II interferons, of which 
IFNγ is the only member; and type I interferons (IFN-I), which in humans include 13 
isoforms of IFNα and one isoform each of IFNβ, IFNε, IFNκ, and IFNω (reviewed in 
(76)). Induction of IFN-I begins with the sensing of microbial- and danger-associated 
molecular patterns—primarily nucleic acids—by PRRs on the cell surface, in endosomes, 
and in the cytosol. These receptors then trigger signaling cascades through one of four 
adaptor molecules: mitochondrial antiviral-signaling protein (MAVS), MYD88, STING, 
and TRIF. These signaling cascades lead to the phosphorylation of the transcription 
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factors IRF3 and IRF7, which translocate to the nucleus and promote transcription of 
IFN-I. All IFN-I signal through the IFNα receptor (IFNAR), a heterodimer of IFNAR1 
and IFNAR2. In addition to their importance in host antiviral defense, IFN-I function in 
host response to bacterial infection and modulation of both the innate and adaptive 
immune systems ((77, 78)).  
In patients, IFNα levels in the blood positively correlate with parasitemia in 
Plasmodium falciparum infection (79), and polymorphisms in IFNAR1 are associated 
with protection from CM (72, 80). Recently, multiple groups have shown that deletion of 
Ifnar1 or both Irf3 and Irf7 protect mice from ECM (55, 72-74). Although daily 
administration of exogenous IFNα throughout PbA infection drastically decreased 
parasitemia and protected most mice from ECM (81), the ECM protection conferred by 
Ifnar1 deletion does not appear to depend on parasitemia, as various groups have found a 
decrease (74), no change (55, 73), or increase (72) in parasitemia in ECM-resistant 
Ifnar1-/- mice compared to ECM-susceptible wild-type (WT) mice. Adoptive transfer of 
Ifnar1+/+ CD8+ splenocytes, but not Ifnar1-/- CD8+ splenocytes, from PbA-infected mice 
is sufficient to make Ifnar1-/- mice susceptible to ECM; however, IFN-I do not appear to 
be necessary for activation of CD8+ T cells, as similar numbers of activated CD8+ T cells 
accrue in the spleens of WT and Ifnar1-/- mice (72). IFN-I have also been implicated in 
modulation of the adaptive immune system. One group found that deleting Ifnar lead to a 
decrease in parasitemia in both the PbA and P. chaubaudi mouse malaria models because 
IFN-I inhibited IFNγ production by CD4+ T cells (82). In a later paper, this group found 
that IFN-I block proinflammatory cytokine production by human PBMCs taken from 
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individuals experimentally infected with P. falciparum and then rechallenged ex vivo 
with iRBCs as well as promote the production of CD4+ IL-10 producing type 1 regulatory 
T (Tr1) cells (83). 
Multiple cell types and signaling pathways have been implicated in production of 
IFN-I during Plasmodium infection. In experimental human infection with P. falciparum, 
increased numbers of CD56+ cells are IFN-I positive compared to pre-infection (83). 
Hepatocytes produce IFN-I in response to PbA sporozoite RNA in a MAVS-dependent 
manner, and these IFN-I help the host control the liver-stage parasite burden (84). Both 
cDCs and plasmacytoid dendritic cells (pDCs) produce IFN-I in the spleen during PbA 
infection (85, 86), and splenic red pulp macrophages (RPMs) drive early production of 
IFN-I during infection with the related parasite P. chabaudi, which does not cause ECM 
(87). However, these RPMs are not required for control of P. chabaudi parasitemia (87), 
and only cDCs, not pDCs, are necessary for PbA-induced ECM (85), so it is unclear if 
these IFN-I are relevant to malaria-induced pathology. Recent work on CD11c-Cre 
Ifnar1fl/fl mice, in which Ifnar1 is deleted almost exclusively in cDCs, showed that these 
mice were completely resistant to ECM, and this protection correlated with a 50% drop in 
serum IFNα as compared to ECM-susceptible Ifnar1fl/fl littermate control mice (86). This 
drop in serum IFNα is almost certainly due to interruption of a positive feedback loop in 
cDCs. The endosomal DNA sensor TLR9, which is important for production of IFN-I in 
pDCs, recognizes Plasmodium DNA bound to Hz (49), and the endosomal RNA sensor 
TLR7 is essential for early production of IFN-I induced by P. chabaudi (88). Although 
the drug E6446, which inhibits both TLR7 and TLR9, protects mice from PbA-induced 
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ECM (89), deletion of Tlr7 or Tlr9 provides little to no protection from ECM (90-92), 
and TLR7 is dispensable for P. chabaudi parasite control (88), so E6446 may function as 
a general blocker of nucleic acid sensing rather than a specific inhibitor of TLRs 7 and 9. 
At the adaptor level, the importance of MYD88, which is downstream of both TLR7 and 
TLR9, to ECM pathogenesis is unclear, as some research has shown either a partial or 
complete protection from ECM for Myd88-/- mice (90, 92, 93), while other experiments 
have shown that Myd88-/- mice remain susceptible to ECM (91). The adaptor TRIF, 
required for induction of IFN-I downstream of TLR3 and TLR4, is completely 
dispensable for ECM pathogenesis (90, 91). STING, an adaptor protein important for 
cytosolic DNA sensing, is essential for recognition of a common AT-rich motif found 
within Plasmodium genomic DNA, and mice expressing a non-functional hypomorph of 
TBK1—which normally phosphorylates IRF3 downstream of STING (94)—are 
completely resistant to ECM (55). Still, the upstream signaling pathway essential for 
production of these IFN-I remains unknown. Given the discovery of cGAS and its well-
described role in detecting cytosolic DNA, we hypothesize that cGAS is the sensor for 
cytosolic P. falciparum gDNA and AT-rich ODNs and is required for the resulting 
expression of IFN-I. 
 
Innate immune memory 
Traditionally, it was believed that immune memory was exclusively a component of the 
adaptive immune system. However, multiple studies in the past few years have 
demonstrated memory phenotypes in innate immune cells. Mihai Netea and colleagues 
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demonstrated that initial stimulation of human monocytes with β-glucan—a component 
of fungal cell walls—followed by washing of the cells and a rest period with no stimulus, 
provoked increased cytokine production upon secondary stimulation with TLR ligands 
(95). Similarly, administration of the bacille Calmette-Guérin (BCG) vaccination—the 
primary vaccine against tuberculosis—to healthy volunteers induced increased monocyte 
responsiveness to both bacterial and fungal pathogens up to three months after 
vaccination (96). In both instances, this memory phenotype appeared to be mediated by 
epigenetic modifications, specifically increased trimethylation at histone H3 lysine 4 sites 
(H3K4me3), because treatment with a methyltransferase inhibitor to prevent histone 
methylation abrogated this training effect in both studies. Netea and colleagues coined 
the term “trained immunity” to described these increased, non-specific secondary innate 
immune responses (97). The converse of trained immunity, tolerance, occurs when an 
initial stimulation renders innate immune cells hyporesponsive to subsequent immune 
challenge. Lipopolysaccharide (LPS) tolerance is a classical example, and this tolerance 
is seen clinically in sepsis and systemic inflammatory response syndrome (SIRS) (98). 
An increasing amount of evidence supports the idea that post-sepsis tolerance is at least 
partially due to epigenetic changes in traditional innate immune cell lineages (99). In 
opposition to trained immunity, LPS tolerance appears to be regulated in part by loss of 
H3K4me3 at proinflammatory promoters upon secondary challenge (100). Global 
epigenomic and transcriptomic analysis of β-glucan-trained and LPS-tolerized 
macrophages discovered differential regulation of gene modules between these two 
functional states (101). Trained immunity seems to be at least in part dependent on 
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cellular metabolism, as the phenotype is correlated with a shift toward aerobic glycolysis, 
and chemical inhibition of the AKT/mammalian target of rapamycin (mTOR)/hypoxia-
induced factor 1α (HIF1α) pathway blocks training (102). Blocking BCG-induced 
training using the mTOR inhibitor rapamycin also blocks the increase in H3K4me3 at 
proinflammatory promoters (103), while tolerant monocytes from patients with septic 
shock have defective glycolytic and oxidative phosphorylation pathways (104). 
Interestingly, tolerance and training appear to be two ends of the same spectrum, as LPS 
and other ligands that induce tolerance can also induce training at much lower 
concentrations (105). This can be summarized by the following model: an initial immune 
challenge serves as a priming stimulus, which, depending on the nature and concentration 
of the priming ligand, induces epigenetic and metabolic alterations that result in a trained 
or tolerized response to subsequent immune challenge. 
McCall and colleagues demonstrated that whole blood samples isolated from 
volunteers infected experimentally with P. falciparum produced elevated 
proinflammatory cytokines upon TLR ligand stimulation; additionally, naïve PBMCs 
primed ex vivo with P. falciparum lysate and then immediately re-stimulated with TLR 
ligands produced increased proinflammatory cytokines than PBMCs primed with media 
alone (106). Subsequently, our group confirmed that the hyperresponsiveness of malaria-
primed PBMCs to TLR ligand stimulation is conserved in naturally acquired febrile P. 
falciparum infection, and, through the use of P. chabaudi infection in mice, demonstrated 
that this priming is IFNγ- and at least partially TLR9-dependent (107). Children who 
presented to a Gabonese hospital with uncomplicated malaria and whose PBMCs 
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produced IFNγ after stimulation with malarial proteins had lower rates of malaria 
reinfection than children with severe malaria or children with mild malaria whose 
PBMCs did not produce IFNγ to malarial protein challenge (108). Similarly, Eleanor 
Riley’s group demonstrated that febrile malaria patients whose PBMCs produced IFNγ 
upon stimulation with iRBCs were less likely to have malarial disease and infection on 
follow-up (109). These results indicate that this IFNγ-dependent, malaria-induced 
priming could induce a memory component.  
On the other hand, a lengthier exposure to malarial infection can also induce 
tolerance to subsequent infection (110). A recent reanalysis of historical experimental P. 
falciparum infection data demonstrated that the pyrogenic threshold—the level of 
parasitemia required to provoke fever—was higher for individuals after reinfection 
compared to initial infection (111).  In holoendemic areas, where malaria is transmitted 
year-round, many individuals have blood parasitemias that would cause fever in naïve or 
occasionally exposed individuals, but they remain asymptomatic. The tolerance induced 
by malarial infection also extends to non-malarial infection or immune challenge. In the 
Gambia, recent malarial infection appeared to predispose children to nontyphoid 
Salmonella bacteremia (112). Acute malarial disease inhibited the immune response to 
Salmonella typhi or meningococcal vaccination, and this depressed response to 
meningococcal vaccination persisted one month after presentation of febrile malaria 
(113). Analogous to LPS tolerance, individuals with experimental P. vivax malaria (114) 
or malaria as fever therapy for neurosyphilis (115) exhibited depressed febrile responses 
to subsequent experimental endotoxin challenge. As discussed by McCall and colleagues 
		
	
	
	
19	
(106), these endotoxin challenge studies differed from the studies demonstrating priming 
in that the endotoxin challenges were performed during recovery from the peak febrile 
response, while the priming studies were performed during the febrile response. 
Similarly, DCs isolated from spleens of mice on day 17 post-infection with P. chabaudi 
showed depressed proinflammatory cytokine production upon TLR ligand stimulation, 
while this depression was not seen in DCs isolated three days after infection (116). Given 
that malaria induces priming early in vivo and in vitro and can induce tolerance after 
prolonged infection or multiple infective episodes, we hypothesize that P. falciparum 
can also induce trained innate immunity in an in vitro model of innate immune 
memory. 
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Chapter II: Materials and Methods 
Ethics statement  
The protocol and consent forms for experiments with human samples were approved by 
the Institutional Research Boards from the University of Massachusetts Medical School 
(IRB H-14839 and H-10368), Centro Internacional de Entrenamiento e Investigaciones 
Medical-CIDEIM (CIEIH-1249), University Hospitals Cleveland Medical Center IRB 
(06-11-22), and the Kenya Medical Research Institute Ethical Review Committee (SSC 
No: 2207). All experiments involving animals were performed in accordance with 
guidelines set forth by the American Association for Laboratory Animal Science and 
were approved by the Institutional Animal Care and Use Committee (A-1332) at the 
University of Massachusetts Medical School. 
 
Malaria cultures and iRBC/hemozoin isolation 
Plasmodium falciparum clone 3D7 was cultured utilizing a candle jar technique as 
described previously (117), substituting AlbuMAX II (Gibco) for human serum. iRBCs 
were isolated by passing the P. falciparum culture through a magnetic field (MACS LD 
column, Miltenyi Biotec); this resulted in enrichment consistently ³90% iRBCs in the 
trophozoite or schizont stage. Enrichment was performed on the day the iRBCs were to 
be used, and they were then kept on ice until used to stimulate immune cells. Similarly, 
Hz was isolated by passing discarded malaria culture media through an LD column. The 
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Hz was then dried, weighed, resuspended in phosphate-buffered saline (PBS), and frozen 
at -20°C until use. 
 
Isolation of P. falciparum genomic DNA (gDNA) 
P. falciparum culture (~30% parasitemia) observed by Giemsa stain under light 
microscopy to be at the trophozoite stage was harvested and parasites from iRBCs were 
released by treatment with 0.2% saponin. The released parasites were pelleted at 3000 x g 
for 20 min, washed with cold PBS, and incubated in PBS with proteinase K (25 µg/ml) at 
56 °C for 10 min. The resultant P. falciparum gDNA-containing solution was then 
extracted with phenol/chloroform/isoamyl alcohol and centrifuged at 10,000 x g for 10 
min. The parasite DNA was precipitated overnight with NaOAc and absolute ethanol at -
80°C, then washed with 70% ethanol and suspended in nuclease and endotoxin-free 
water. After determining DNA concentration by absorption at 260 nm, the P. falciparum 
gDNA was stored at -20°C. The purity of P. falciparum gDNA was confirmed by PCR 
using primers for Plasmodium 18S RNA as described previously (118) and human TLR7 
genes.  
 
Human primary cell isolation and preparation (for Chapter III) 
Peripheral blood mononuclear cells (PBMCs) from healthy human donors were obtained 
as described previously using Ficoll gradient separation (119). Human primary CD14+ 
monocytes were purified from PBMC using the Pan Monocyte isolation kit (Miltenyi 
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Biotec) and magnetic separation according to the manufacturer’s instructions. Monocyte 
derived macrophages (MDMs) were obtained by adherence and differentiation of 
adherent PBMCs in RPMI 1640 containing 10% fetal bovine serum (FBS) for 7 days.  
 
Mouse primary cell isolation and preparation 
Primary bone marrow derived macrophages (BMDMs) from C57BL/6 mice were 
generated as described previously (120) utilizing L929 conditioned media as the source 
for macrophage colony-stimulating factor (M-CSF) and cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) (GIBCO-BRL) supplemented with 2 mM glutamine and 10% 
FBS. Mouse non-thioglycollate-elicited peritoneal exudate cells (PECs) were prepared as 
described previously (121) For stimulations, poly(dA:dT), interferon stimulatory DNA 
(ISD), P. falciparum gDNA, Hz, and AT-rich ODNs were transfected at the indicated 
concentrations using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions. Sendai virus (SeV, Cantrell strain, 20 U/ml) was used as a control where 
indicated. DNase digestion of P. falciparum gDNA and hemozoin was performed using 
DNase I (Qiagen) according to the recommended protocol. Primary cells and cell lines 
were stimulated as stated and collected after the described time points for RNA extraction 
or cell lysate preparation.  
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Human cell lines 
Human pro-monocyte THP-1 cells (WT [cGAS+/+/IFI16+/+], cGAS-/-, and IFI16-/-) were 
generated as previously described using clustered regularly interspaced short palindromic 
repeats (CRISPR)/Cas9 genome editing technology (122). WT and knockout THP-1 cells 
were grown in RPMI 1640 supplemented with 2 mM L-glutamine with 10% FBS. THP-1 
cells were differentiated into macrophages by treating with 100 nM phorbol 12-myristate 
13-acetate (PMA) (Chapter III) or 5 ng/mL PMA (Chapter IV) for 48 hrs (123). BLaER1 
cells were grown and transdifferentiated as described previously (124). 
 
Kenyan field samples 
Pediatric malaria samples were obtained as part of a longitudinal cohort study conducted 
at the Chulaimbo Sub-County Hospital outpatient clinic in Kisumu County, Kenya. 
Participants enrolled in this observational cohort included children aged 1-10 years with 
acute uncomplicated malaria diagnosed by light microscopy. All cases of uncomplicated 
malaria were febrile (temperature ³ 37.5°C) and without signs or symptoms of severe 
malaria. Thick and thin blood smears were prepared from all blood samples. A slide was 
deemed negative when no parasites were seen after counting microscopic fields 
containing at least 200 leukocytes. Children with acute uncomplicated malaria were 
treated with artemether/lumefantrine per Kenyan Ministry of Health guidelines and 
followed up at 2 and 6 weeks. At 2 weeks, finger prick blood samples were obtained for 
blood smear to ensure parasite clearance. Venous blood samples were obtained from 
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cases with acute malaria at the time of presentation (before administration of the first 
dose of artemether-lumefantrine) and 6 weeks following treatment. Submicroscopic 
blood stage infections were detected at 6 week recovery visits by a nested polymerase 
chain reaction (PCR) assay targeting P. falciparum-specific small subunit ribosomal 
RNA genes (118). PBMCs were separated by Ficoll-Hypaque density gradient 
centrifugation and cryopreserved as previously described (125). Monocytes were 
negatively selected from thawed PBMCs using the Pan Monocyte Isolation Kit (Miltenyi 
Biotec). 
 
Human adherent PBMC isolation and stimulation (trained immunity assay) 
Leukopaks (enriched leukapheresis products; New York Biologics) or whole blood drawn 
from healthy human donors was diluted 1:1 with sterile PBS (Gibco) and layered over 
Ficoll-Paque PLUS (GE) for density gradient centrifugation. The buffy coat was then 
harvested, washed twice with sterile medium, and incubated for 3 min in RBC lysis 
buffer (Roche). To remove any residual platelets, cells were washed 3x in PBS 
supplemented with 2% FBS and centrifuged 10 min at 120xg with no break. The washed 
PBMCs were resuspended in RPMI 1640 media (Gibco) supplemented with sodium 
pyruvate (Sigma), L-glutamine (Gibco), and gentamicin (Gibco) to concentrations of 10 
mM, 10 mM, and 10 ng/mL, respectively. PBMCs were then plated at 5x105 cells/well 
(in 96-well round-bottom plates) or 10x106 cells/well (in 6- or 12-well flat-bottom plates) 
and incubated at 37°C for ³1 hr, after which the non-adherent cells were removed by 
washing 3x with warm PBS. The adherent PBMCs were then incubated in similarly 
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supplemented RPMI with 10% human serum (RPMI+) and stimulated for 24 hours. Cells 
were then washed with warm PBS and allowed to rest in RPMI+ for three or five days. 
After the rest period, cells were either harvested for chromatin immunoprecipitation 
(ChIP) analysis or challenged with 10 µg/mL Pam3CSK4 (Invivogen) or 10 ng/mL LPS 
(Sigma) for 4-24 hours. Stimulated cells were harvested for mRNA analysis or 
supernatants were frozen at -20°C for subsequent cytokine measurement (Fig. 2.1). 
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Figure 2.1. Schematic of in vitro trained immunity assay. Cells were treated with media 
alone (RPMI+), iRBCs, uRBCs, or Hz for 24 h and then washed 3x with warm PBS. 
Cells were then rested for 3-5 d in RPMI+. At the conclusion of the rest period, cells 
were either harvested for ChIP analysis or challenged with the TLR ligands LPS (10 
ng/mL) or Pam3CSK4 (10 µg/mL) for 4-24 h, after which mRNA was harvested from 
cells or supernatants were assayed by ELISA. 
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Negative selection of monocytes (Chapter IV) 
The trained immunity assay was also performed on a population of enriched, negatively 
selected monocytes. This population was obtained by using the EasySep Human 
Monocyte Enrichment Kit without CD16 depletion (STEMCELL Technologies) 
according to the manufacturer’s instructions. 
 
Enzyme-linked immunosorbent assays (ELISAs) 
Chapter III: ELISA for mouse IFNß protein was performed as described in detail 
previously (126). 
Chapter IV: Production of human TNFa and IL-6 or mouse TNFa and Regulated on 
Activation, Normal T cell Expressed and Secreted (RANTES) were measured in the cell 
supernatants after 24 hrs of Pam3CSK4 or LPS stimulation with ELISA kits (R&D) 
according to the manufacturer’s specifications. A MTS tetrazolium dye assay [3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
inner salt] (Promega) was used according to the manufacturer’s instructions to determine 
relative cell number post stimulation. Briefly, after removing supernatants from cells, 
cells were incubated with 120 µl/well RPMI+ with 20% of MTS/phenazine methosulfate 
(PMS) (Sigma) mixture and incubated for 2-20 h at 37°C. Solutions were then transferred 
to ELISA plates and read at 490 nm. Absorbance values were normalized by subtracting 
the absorbance values for no-cell blank wells. Relative cell numbers were determined by 
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dividing each absorbance value by the mean absorbance value for RPMI+ trained/RPMI+ 
challenged wells. Cytokine values were then normalized to these relative cell numbers.  
 
Flow cytometry 
After primary stimulation and three-day rest, supernatants were removed and adherent 
PBMCs incubated in PBS containing 1 mM ethylenediaminetetraacetic acid (EDTA) for 
10-15 min at 37°C. Contents of the wells were pipetted up and down vigorously for ~5 
min to detach adherent PBMCs from the wells. Cells were transferred to new tubes and 
efficient cell removal from plates was confirmed by inspection under light microscopy. 
Cells were then washed in PBS containing 1% bovine serum albumin (BSA), 
resuspended in PBS with 1% BSA, and stained for 20-30 min on ice with the following 
fluorescently-labeled antibodies according to the manufacturer’s instructions: anti-CD3-
phycoethrin-cyanine7 (PE-Cy7), anti-CD4-allophycocyanin (APC), anti-CD8-PE, anti-
CD14-Pacific Blue, anti-CD19-fluorescein isothiocyanate (FITC), anti-CD45-APC-Cy7, 
and anti-CD56-peridinin-chlorophyll-Cy5.5 (PerCP-Cy5.5), as well as live-dead Aqua 
stain. All flow cytometry experiments were performed on a LSR II flow cytometer (BD 
Biosciences) with compensation levels set using single-antibody controls. Data was 
analyzed using FlowJo software (Tree Star).  
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mRNA expression 
Total RNA was extracted using the Trizol (Invitrogen) or the RNeasy Mini Kit (Qiagen) 
according to the manufacturer’s instructions. RNA was then quantified using a NanoDrop 
spectrophotometer (Thermo). cDNA synthesis and qPCR assay were performed using an 
iScript cDNA synthesis kit and iQ SYBR Green supermix (both Bio-Rad), respectively. 
Data was normalized to ACTB and/or GAPDH expression and analyzed using Bio-Rad 
software. NanoString analysis was performed using the nCounter Human Inflammation 
v2 Codeset, and the data was analyzed using NanoString software. Hierarchical 
clustering heatmaps of the NanoString expression data were prepared in R using a 
package described here: https://cran.r-project.org/web/packages/heatmap3/heatmap3.pdf.  
 
Detection of IRF3 phosphorylation  
Cell lysates were prepared in RIPA lysis buffer as described previously (127), subjected 
to SDS-PAGE and visualized by Western Blotting using antibodies against phospho-
IRF3 (S386) (Abcam), total IRF3 (D614C) (Cell Signaling Technology), and ß-actin 
(Sigma).  
 
Preparation of Cytosol for Analysis of Endogenous 2’3’-cGAMP  
THP-1 cells were transfected with P. falciparum gDNA and cytosolic extracts from ~1.8 
x 107 cells were prepared by hypotonic lysis. Briefly, cells were incubated in hypotonic 
buffer (10mM Tris-HCl (pH 7.4), 10 mM KCl, 1.5 mM MgCl2) for 30 minutes and then 
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dounce-homogenized x 100 strokes. Cell lysates were heated at 95°C for 5 min and then 
centrifuged at 17,000 x g for 10 min to remove denatured proteins. The heat resistant 
supernatant was recovered and stored at -80°C until LC-MS/MS analysis.  
 
Quantification of 2’3’-cGAMP by Liquid Chromatography-Tandem Mass 
Spectrometry (LC-MS/MS) 
Quantification of 2’3’-cGAMP was performed by LC-MS/MS as described previously 
(122). Briefly, extraction of 2’3’-cGAMP from cell lysates was performed with 
acetonitrile/methanol/water (2/2/1, vol/vol/vol) buffer. 5 ng of heavy-labeled 2’3’-
cGAMP was added to each sample as an internal standard. The samples were then heated 
to 95°C for 10 min, cooled on ice for 10 min, and then centrifuged at 17,000 x g for 10 
min to remove denatured proteins. The remaining supernatants were dried in a roto 
Speedvac, and the lyophilized material from each sample was resuspended in 50 µl water. 
10 µl of sample was then injected per technical replicate. Ratios of endogenous 2’3’-
cGAMP to heavy-labeled 2’3’-cGAMP were compared to a standard curve of light:heavy 
2’3’-cGAMP prepared in human PBMCs to quantify endogenous 2’3’-cGAMP in each 
sample. 
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Neutralizing antibodies and inhibitors 
Mouse anti-human IL-12p40 IgG1 was from R&D. Both mouse anti-human IFNg IgG1 
and mouse IgG1 isotype control were from Biolegend. 5’-methylthioadenosine (MTA) 
and rapamycin were from Sigma. 
 
Chromatin precipitation (ChIP) analysis 
ChIP was performed using a rabbit anti-human H3K4me3 IgG antibody (Diagenode) and 
ChIPed DNA was then further analyzed via qPCR as described previously (96). Briefly, 
cells were fixed in 1% formaldehyde for 10 min and then quenched with glycine. Cells 
were then washed, counted, and resuspended in lysis buffer and sonicated using a 
Bioruptor UCD-300 (Diagenode) for four cycles of 10 x (30 sec ON, 30 sec OFF) on the 
HIGH setting. ChIP was performed on the sonicated chromatin using either a rabbit anti-
human H3K4me3 IgG antibody (Diagenode) or a control rabbit IgG antibody (Abcam) 
conjugated to Sheep anti-rabbit Dynabeads (Life Technologies). After ChIP, 
chromatin:bead complexes were washed 2x in each of low salt, high salt, lithium chloride 
(LiCl)-containing, and Tris-EDTA (TE) buffers. Chromatin was then eluted from the 
beads and decrosslinked to isolate the DNA. DNA was then purified and quantified using 
qPCR as described above. For all ChIP experiments, qPCR values were normalized as 
percent recovery of the input DNA. 
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Statistical Analysis 
Chapter III: Differences in paired groups were analyzed with paired t-tests. When ratios 
to controls were compared, one sample paired t-tests (H0 log(ratio)=0) were performed on 
log-transformed ratio values. Otherwise, data were analyzed using an unpaired, two-
tailed Student’s t test correcting for multiple comparisons using the Holm-Sidak method. 
Analyses were performed with GraphPad Prism 7 software (GraphPad Inc., San Diego, 
CA). 
Chapter IV: For experiments with multiple replicates for an individual donor performed 
on different days, several sensitivity analyses were carried out. Four different statistical 
analyses were performed for the experiments represented in Fig. 1B-C: a mixed model 
regression analysis, a Wilcoxon signed-rank test with clustering (analysis at the replicate 
level accounting for correlation of data within donor), a Wilcoxon signed-rank test using 
one averaged value per donor (mean of all replicates), and a paired t-test using one 
averaged value per donor. All four tests provided nearly identical hypothesis decisions 
with an a=0.05, so paired t-tests using one value per donor was used for all other 
experiments. When ratios to controls were compared, one sample t-tests (H0 log(ratio)=0) 
were performed on log-transformed ratio values. For experiments comparing three groups 
a non-parametric ANOVA was used (Kruskal-Wallis).   
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Abstract 
Innate immune receptors have a key role in the sensing of malaria and initiating immune 
responses. As a consequence, systemic inflammation emerges and is directly related to 
signs and symptoms during acute disease. Here we demonstrate that Plasmodium 
falciparum genomic DNA delivered to the cytosol of human monocytes binds and 
activates the cytosolic DNA receptor cGAS. Activated cGAS synthesizes 2’3’-cGAMP, 
which we subsequently detect using mass spectrometry. 2’3’-cGAMP acts as a second 
messenger for STING activation and triggers STING/TBK1/IRF3 activation, resulting in 
type IFN-I production in human cells. This induction of IFN-I was independent of the 
IFI16 receptor. Access of DNA to the cytosolic compartment is mediated by hemozoin, 
since incubation of cultured malaria hemozoin pigment with DNase abrogated IFNß 
induction. Collectively, these observations implicate cGAS as an important cytosolic 
sensor of Plasmodium falciparum DNA and reveal the role of the cGAS/STING pathway 
in the induction of IFN-I in response to malaria parasites.  
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Introduction 
Malaria remains a major cause of morbidity and mortality worldwide. The World Health 
Organization has estimated that there were ~212 million cases of malaria globally in 
2016 and about 429,000 deaths, primarily (~70%) occurring in children under age 5 (1). 
Despite many gains against the disease, the problems associated with malaria eradication 
remain significant. These include increasing resistance of insect vectors to insecticides 
and the emerging resistance of Plasmodium to the most efficacious antimalarial drugs 
(128). Current evidence indicates that drug resistance to artemisinin derivatives, the last 
generation treatment for asexual blood-stage infection, has developed in Southeast Asia 
and Africa (129-131). Despite these setbacks, the efforts continue with the objective to 
achieve the global elimination of malaria.   
Our understanding of the pathogenesis of malaria is still limited (132). Therefore, 
a top priority in basic research is to dissect the mechanisms involved in malaria disease 
development and provide new approaches for therapeutic and prophylactic interventions 
since a highly effective malaria vaccine is still unavailable. An important component of 
the pathogenesis of malaria is the host innate immune response to the parasite. The 
activation of innate immune cells and the associated systemic inflammation leads to the 
initial signs and symptoms of disease and can influence the development of severe 
disease (133). Inflammatory mediators during malaria infection are produced as a result 
of direct recognition of malarial PAMPs (pathogen-associated molecular patterns) by 
innate immune receptors, including TLRs (133), NLRs and other nucleic acid sensors 
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(55). Concomitant with TLR activation, expression of sensor proteins including NLRs is 
augmented and NLR-containing inflammasomes are assembled. Pro-inflammatory 
cytokines and mediators like TNFα, IL-12, caspase-1 and IL-1ß are then released (53). 
Elevated expression of interferon-stimulated genes (ISGs) in innate immune cells is also 
characteristic during Plasmodium infection (55, 134).  
The recognition of microbial DNA by the immune system provides a general 
mechanism for the detection of pathogens (135, 136). Delivery of foreign or self DNA 
into the cytoplasm (which is largely free of self DNA) through microbial infection or cell 
damage can activate cytosolic DNA sensors (137). Plasmodium DNA represents a major 
trigger of innate immunity during infection (49, 51, 55). The Plasmodium genome 
contains highly stimulatory CpG motifs, which are thought to activate TLR9 when 
carried into the phagolysosomal compartment by the malaria pigment hemozoin (Hz) (49, 
51). However, CpG-rich motifs are relatively rare in Plasmodium falciparum (P. 
falciparum). In contrast, AT-rich DNA motifs are present in abundance and induce IFN-I 
via a pathway that is independent of TLRs, DAI, RNA polymerase III and IFI16/p204 but 
dependent on STING (138, 139), TBK1 (120, 140), and IRF3 and IRF7 (55, 141).  
The enzyme cyclic GMP-AMP synthase (cGAS) has been identified as a cytosolic 
DNA sensor whose activation results in the subsequent activation of STING (42, 43). 
Specifically, in the presence of cytosolic double-stranded DNA, cGAS catalyzes the 
synthesis of cyclic GMP-AMP (2’3’-cGAMP) from ATP and GTP. 2’3’-cGAMP then 
functions as a second messenger that binds to and activates STING. Activated STING 
leads to IRF3 phosphorylation and IFN-I production and expression of ISGs (44). Here, 
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we report that cGAS has an important role as a sensor of P. falciparum genomic DNA. 
Our data suggest that 2’3’-cGAMP acts as a second messenger after the sensing of P. 
falciparum genomic DNA and other malaria PAMPs to induce IFN via the cGAS/STING 
pathway. We suggest that cGAS detection of cytosolic malaria DNA is an important 
molecular feature of malaria pathogenesis.  
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Results 
IFN-I are induced in human primary myeloid cells in response to P. falciparum gDNA  
In our previous work, we demonstrated that Plasmodium falciparum iRBCs—but not 
uninfected RBCs (uRBCs)—stimulated IFNB expression in human PBMCs, and IFNB 
expression was also induced by the transfection of P. falciparum genomic DNA (gDNA) 
in these cells (55). We extended these studies to determine the direct effect of P. 
falciparum on IFN-I induction in purified human myeloid cells. CD14+ monocytes were 
stimulated with iRBCs or with uRBCs as controls. A significant induction of IFNB 
mRNA was observed with iRBC stimulation. Although stimulation of CD14+ monocytes 
with heterologous uRBCs did induce slightly increased expression of IFNB mRNA as 
compared to media-stimulated controls, stimulation with iRBCs induced significantly 
increased IFNB expression as compared to uRBCs (Fig. 3.1A). The induction of IFNB by 
iRBCs was similar to that elicited by transfection of P. falciparum gDNA (Fig. 3.1A). 
IFNα was also induced at the mRNA level (data not shown).  
Previous results from our group demonstrated that Hz presents Plasmodium DNA 
to TLR9 (49). Like CD14+ monocytes, monocyte-derived macrophages (MDMs) 
expressed IFNB mRNA in response to transfection of P. falciparum gDNA (Fig. 3.1B). 
We also determined whether other malarial products would induce IFNB expression in 
MDMs. Hz strongly stimulated IFNB expression in a dose-dependent manner when 
delivered into the cytosol of MDMs (Fig. 3.1B). Likewise, other known IFN-I inducers—
poly (dA:dT), ISD, and Sendai virus (SeV)—as well as AT-rich ODNs containing 
secondary stem-loop structure (AT5 and AT5 3x) significantly promoted IFNB 
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expression in MDMs (Fig. 3.1C). Collectively, these data indicate that both malaria 
parasites and malarial PAMPs (P. falciparum gDNA, Hz, AT-rich ODNs) activate IFN-I 
in human primary myeloid cells.  
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Figure 3.1. Human primary myeloid cells express IFNB in response to P. falciparum 
iRBCs and malarial DNA ligands. (A) CD14+ monocytes were isolated from healthy 
human donor PBMCs by magnetic bead selection and incubated with uRBCs, iRBCs, or 
transfected with P. falciparum gDNA (10 µg/ml). RNA was prepared 6 h later and IFNB 
was measured by qRT-PCR. (B-C) Human monocyte-derived monocytes were 
transfected with PBS alone, natural hemozoin (Hz), or P. falciparum gDNA (B). AT-rich 
oligodeoxynucleotides (ODNs) AT5 and AT5 3x (3 µM) were also transfected into 
MDMs, and interferon-stimulatory DNA (ISD), p(dA:dT) and Sendai virus (SeV) were 
used as positive controls (C). IFNB levels measured as in (A). Each dot represents a 
single donor. Each horizontal bar represents mean ± SEM for six donors (A), four or five 
donors (B) or three donors (C) (all comparisons in (A) to medium-stimulated cells unless 
otherwise indicated, *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, paired t-test).  
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IFN-I are induced after cytosolic delivery of malarial DNA 
We determined the role of cytosolic delivery of DNA in the ability of Hz to induce IFNB 
expression in THP-1 cells. Hz significantly induced IFNB expression in a dose-dependent 
manner when transfected into cells. This activity was abolished when Hz was pretreated 
with DNase I (Fig. 3.2A). Similarly, purified P. falciparum gDNA induced IFNB when 
delivered to the cytosol of THP-1 cells in a dose and time-dependent manner (Figs. 3.2B 
and 3.2C).  
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Figure 3.2. IFN-I are induced by P. falciparum gDNA. (A) The indicated amounts of Hz 
or P. falciparum gDNA (10 µg/mL) were either treated with DNase I or not treated, and 
then transfected into THP-1 cells for 6 h followed by measurement of IFNB mRNA 
expression by qRT-PCR. Each dot represents the result of an individual experiment, and 
horizontal bars represent mean ± SEM for three independent experiments (all 
comparisons between No DNase and DNase I-treated cells, *p<0.05, **p<0.01, paired t-
test). (B) THP-1 cells were transfected with the indicated concentrations (µg/ml) of P. 
falciparum gDNA for 6 h followed by measurement of IFNB mRNA by qRT-PCR. Dots 
represent mean ± SEM for two independent experiments. (C) Time course of induction of 
IFNB mRNA in THP-1 cells transfected with 50 µg/ml of P. falciparum gDNA or 
lipofectamine alone for the indicated time periods. Dots represent mean ± SEM for two 
or three independent experiments. 
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IFN-I induction by P. falciparum gDNA is dependent on cGAS.  
cGAS is a DNA sensor that catalyzes the synthesis of 2'3'-cGAMP to drive activation of 
STING, resulting in the induction of IFN-I and other inflammatory genes (42, 43). In 
order to determine the involvement of cGAS as a sensor for Plasmodium DNA, IFNB 
expression was assessed in cGAS KO and WT THP-1 cells. Transfection of cultured Hz 
or P. falciparum gDNA induced expression of IFNB mRNA in WT but not in cGAS-
deficient THP-1 cells (Fig. 3.3A). Detection of phosphorylated IRF3, an indicator of 
STING activation and an upstream readout for IFN-I induction, revealed phosphorylation 
of IRF3 in WT but not cGAS KO cells when transfected with Hz or P. falciparum gDNA 
(Fig. 3.3B). Cytosolic delivery of AT-rich oligonucleotides (whose design was based on 
sequences from the P. falciparum genome) also induced IFNB in WT THP-1 cells but did 
not induce IFNB expression in cGAS KO cells (Fig. 3.3C). Finally, transfection of IFI16 
knockout cells with P. falciparum gDNA induced equivalent levels of IFNB mRNA to 
WT cells (Fig. 3.3D), suggesting that IFI16 is not required for detection of P. falciparum 
gDNA. Altogether, these results indicate that cGAS is the cytosolic sensor of P. 
falciparum gDNA and is required for the induction of IFNB by P. falciparum DNA or 
malaria hemozoin.  
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Figure 3.3. P. falciparum gDNA induces IFNB expression through the cGAS-STING 
pathway. (A) cGAS+/+ and cGAS-/- THP-1 cells were transfected with the indicated 
quantities of Hz or P. falciparum gDNA for 6 h followed by detection of IFNB mRNA by 
qRT-PCR. Each dot represents the result of an individual experiment, and horizontal bars 
represent mean ± SEM for two independent experiments (all comparisons between 
cGAS+/+ and cGAS-/- cells for each stimulus, *p<0.05, paired t-test) (B) Phosphorylation 
of IRF3 and total IRF3 were detected by SDS-PAGE followed by western blot. Detection 
of ß-actin was used as loading control. (C) cGAS+/+ and cGAS-/- THP-1 cells were 
transfected with AT-rich ODN (AT5 and AT5 3x, 3 µM each) or poly(dA:dT) for 6 h 
followed by detection of IFNB mRNA by qRT-PCR. Stimulation with Sendai virus was 
used as a cGAS-independent control. Each dot represents the result of an individual 
experiment, and horizontal bars represent mean ± SEM for two or three independent 
experiments (all comparisons between cGAS+/+ and cGAS-/- cells for each stimulus, 
**p<0.01, paired t-test) (D) Wild type IFI16 (IFI16+/+) and IFI16 KO (clones 1 and 2) 
THP-1 cells were transfected with 10 µg/ml of P. falciparum gDNA for 6 h and IFNB 
mRNA was measured by qRT-PCR. Bars represent mean ± SD of technical duplicates 
from one experiment. 
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The cGAS-STING pathway is involved in the induction of IFN-I in response to malaria 
DNA 
To corroborate the involvement of the cGAS-STING pathway in the production of IFNß, 
we measured IFNß protein secreted by mouse BMDMs stimulated with P. falciparum 
DNA ligands. Cytosolic delivery of P. falciparum gDNA or AT-rich ODNs induced the 
secretion of IFNß from WT BMDMs (Fig. 3.4). This induction of IFNß protein secretion 
was not observed in either STING KO or cGAS KO macrophages (Fig. 3.4). These data 
indicate the involvement of the cGAS-STING pathway in the induction of IFN-I in 
response to the sensing of P. falciparum DNA.  
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Figure 3.4. IFN-I are produced through the activation of the cGAS-STING pathway in 
response to P. falciparum DNA ligands in mouse primary cells. Bone marrow-derived 
macrophages (BMDMs) from WT, STING-/- and cGAS-/- mice were transfected with P. 
falciparum gDNA (1 µg/ml) or the AT-rich ODNs AT5 and AT5 3x (3 µM). 
Supernatants were recovered after 18 h stimulation and levels of mouse IFNß were 
measured by ELISA. ISD, poly(dA:dT) and SeV were used as controls. Bars represent 
mean ± SD of quadruplicate stimulations of BMDMs from 1 mouse per genotype and are 
representative of 3 independent experiments (all comparisons to WT cells for each 
stimulus, *p<0.05, **p<0.01, ***P<0.001, unpaired t-test corrected for multiple 
comparisons using the Holm-Sidak method). 
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2’3’-cGAMP is induced after sensing of P. falciparum gDNA 
cGAS catalyzes the synthesis of cyclic GMP-AMP (2’3’-cGAMP) in the presence of 
cytosolic DNA (43). To further characterize this activity in response to Plasmodium 
DNA, we transfected THP-1 cells with P. falciparum gDNA and measured 2’3’-cGAMP 
production. We began by heat-treating total extracts of transfected cells, as 2’3’-cGAMP 
is heat-stable. We confirmed the induction of 2’3’-cGAMP in cells transfected with P. 
falciparum gDNA by LS-MS/MS, consistent with the cGAS-dependent induction of 
IFNB shown before in response to P. falciparum gDNA (Fig. 3.3). 2’3’-cGAMP was 
produced in P. falciparum gDNA-transfected THP-1 cells (Fig. 3.5A, panel 2) but not in 
control THP-1 cells (Fig. 3.5A, panel 1; 2’3’-cGAMP peak is represented by one 
asterisk). As a positive control, the lysate from untreated THP-1 cells was spiked with 
synthetic 2’3’-cGAMP (Fig. 3.5A, panel 3). All lysates also included an internal standard 
of 3’3’-cGAMP (500 pg per sample; represented by two asterisks). MS/MS of the 2’3’-
cGAMP peak revealed several fragmented ions with the expected m/z values for product 
ions of 2’3’-cGAMP which were observed in similar ratios in DNA transfected samples 
and spiked controls (Fig. 3.5B), confirming the induction of 2’3’-cGAMP by transfected 
P. falciparum gDNA. To corroborate this result in primary cells, we transfected P. 
falciparum gDNA into MDMs from two donors and used LC-MS/MS to quantify the 
amount of 2’3’-cGAMP produced (Fig. 3.5C). Together our data indicate that the cGAS-
P. falciparum DNA complex activates 2’3’-cGAMP synthesis and consequently the 
induction of IFNß. The data also suggest that cGAS is an important sensor for P. 
falciparum gDNA.  
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Figure 3.5. 2’3’-cGAMP is induced by transfection of P. falciparum genomic DNA. (A, 
B) LC-MS/MS profile from THP-1 isolates. Lysates from THP-1 cells left untreated 
(medium) or transfected with 50 µg/ml of P. falciparum gDNA for 6 h were heated at 
95°C for 5 min to denature proteins. The heat-resistant supernatants were recovered after 
17,000 x g centrifugation. As positive control, lysate from untreated THP-1 cells was 
spiked with 100 nM 2’3’-cGAMP. (A) 1. THP-1 cells untreated (medium), 2. THP-1 
cells transfected with P. falciparum gDNA and 3. THP-1 cells untreated and spiked with 
synthetic 2’3’-cGAMP. Reconstructed ion chromatograms of cGAMP fragment ion at 
m/z 312.049 following LC-MS/MS fragmentation of cGAMP protonated ion. Peaks 
marked with a single asterisk are from endogenous or positive control 2’3’-cGAMP; 
double asterisks indicate 3’3’ cGAMP spiked at 500 pg to each isolate as internal 
standard. (B) Tandem mass spectra (MS/MS) of the peak observed at 6.7 min (from 
corresponding panels A2 and A3). Peaks are 2’3’-cGAMP fragment ions and are 
observed in similar ratios. (C) Quantitation of 2’3’-cGAMP by LC-MS/MS from human 
MDMs transfected with PBS alone or P. falciparum gDNA for 6 h and then processed as 
described in (A). Each dot represents an individual donor. 
PBS Pf gDNA
0
2
4
6
8
10
2’
3’
-c
G
A
M
P 
(n
g/
10
6  c
el
ls
)
+Lipo
0 5 10 15 20 25 30 35 40 45
Time (min)
0
20
40
60
80
100
0
20
40
60
80
100
R
el
at
iv
e 
A
bu
nd
an
ce 0
20
40
60
80
100
9.87
9.66 10.94
9.48
6.74
9.216.77
9.23
THP-1 + Pf gDNA 
(endogenous cGAMP)
THP-1 + medium + 2’3’ cGAMP spike
          (positive control)
THP-1 + Medium
*
*
100 150 200 250 300 350 400 450 500 550 600 650 700
0
50
100
0
50
100 136.0617
312.0491
152.0566
330.0597
392.015597.0283 476.0366
136.0617
312.0490
152.0566
330.0596
97.0282 392.0155 476.0365
m/z
R
el
at
iv
e 
A
bu
nd
an
ce
2’3’ cGAMP
3’3’ cGAMP
internal standard
**
**
**
A
B
1
2
3
C
		
	
	
	
50	
Discussion 
Much progress has been made in our understanding of how phagocytes sense 
Plasmodium and their associated host receptors that elicit inflammation (133). Three 
major P. falciparum PAMPs have been described: GPI anchors (46), hemozoin crystals 
(53) and P. falciparum gDNA (49, 55). Still, the receptor or family of receptors for 
Plasmodium DNA-driven IFN-I responses has been elusive. In previous reports, we 
described “unknown” cytosolic DNA sensor(s) that coupled to a STING, TBK1 and 
IRF3-IRF7 signaling pathway. This receptor or family of receptors acted as a sensor for 
Plasmodium DNA and oligonucleotides containing the AT-rich motif, leading to IFN-I 
production (55). We also revealed that the induction of IFN-I is driven by a pathway that 
did not involve TLR9, DAI, RNA polymerase-III or IFI16/p204 (55). In this report, we 
demonstrate that Plasmodium gDNA induces IFN-I production through cGAS, a 
cytosolic DNA activated enzyme that drives activation of the STING pathway, raising the 
role of IFN-α/ß in malaria pathogenesis.  
The sensing of pathogen-derived DNA is a central strategy used by the innate 
immune system to initiate immune responses following microbial invasion (135). cGAS 
is a cytosolic DNA sensor that activates innate immune responses through production of 
the second messenger 2’3’-cGAMP, which in turn activates the adaptor STING and leads 
to IFN-I production (136). The importance of this cytosolic DNA sensor and IFN-I 
release is now being appreciated in the context of various infectious diseases beyond their 
traditional roles in antiviral immunity. A growing list of pathogens as diverse as 
Neisseria gonorrhoeae (122), Cytomegalovirus (142), Mycobacterium tuberculosis (143), 
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human immunodeficiency virus (HIV) (144), Streptococcus agalactiae (145), Listeria 
monocytogenes (146), and Chlamydia trachomatis (147) all induce IFN-I through the 
cGAS/STING pathway. The data in this paper demonstrate a similar mechanism for 
Plasmodium falciparum.   
Exogenous DNA that gains access to the cytosol is a particularly potent and clear 
danger signal for the innate immune system (136). We have previously demonstrated that 
natural hemozoin activates TLR9 due the delivery of Plasmodial DNA to the endosomal 
compartment (49). However, a TLR9-independent response also occurs when purified 
hemozoin acts as vehicle to deliver Plasmodial DNA into the cytosol leading to IFNß 
production (55). Experimentally, we addressed this hypothesis by transfecting P. 
falciparum genomic DNA with lipofectamine. In contrast to our experimental in vitro 
conditions, hemozoin crystals appear to destabilize the phagolysosome during infection, 
which allows the delivery of phagosomal contents including DNA to the cytosol (53). 
This highlights a mechanism by which hemozoin-associated cargo such as Plasmodial 
DNA might access the cytosol and suggest that P. falciparum gDNA can drive IFNß 
production upon access to the cytosolic compartment.  
Data presented in this study identify the basis of IFN-I production mediated by 
the sensing of cytosolic Plasmodial DNA by cGAS and subsequent activation of the 
cGAS/STING pathway. The consequences of IFN-I induction during malarial infection 
are currently under investigation in several laboratories. Several reports have revealed the 
ability of Plasmodium spp to induce IFN-I and a IFN-I gene signature (49, 83, 88, 134, 
148). Previous reports have shown that exogenous recombinant IFNα can even inhibit 
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experimental cerebral malaria and reduce parasite burden in mice infected with P. 
berghei ANKA (PbA) (149). However, other studies demonstrate that signaling via the 
IFN-I receptor impairs DC function and T cell responses that control parasitemia in 
mouse models of malaria (74). Our studies in the PbA model have demonstrated that the 
TBK1, IRF3-IRF7 dependent production of IFN-I is central to the progression of 
experimental cerebral malaria, given that mice deficient in these factors survived longer 
than wild-type mice (55). A recent report in human malaria identifies an immunological 
regulatory effect of IFN-I during blood-stage P. falciparum infection. IFN-I were found 
to suppress IL-6 but not TNFα production by blood monocytes, promote IL-10-producing 
CD4+ T cells and generate regulatory Tr1 cells (83). Altogether, these data indicate the 
relevant and complex involvement of IFN-I in the pathogenesis of malaria.  
The activation of innate immune cells and consequent systemic inflammation lead 
to the initial signs and symptoms of malaria, and can also influence the development of 
the more severe forms of the disease. The data presented in this paper corroborate the role 
of Plasmodium DNA as a potent PAMP during malaria infection and identify cGAS as an 
important cytosolic sensor that activates the second messenger 2’3’-cGAMP. We also 
reveal the role of the cGAS/STING pathway in the consequent IFN-I production. Our 
results suggest that any attempts at immunomodulatory therapy for patients with severe 
malaria will need to take into account the role of DNA-induced IFN-I and its impact on 
pathogenesis.  
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Abstract 
Malarial infection in naïve individuals induces a robust innate immune response. In the 
recently described model of innate immune memory, an initial stimulus primes the innate 
immune system to either hyperrespond (termed “training”) or hyporespond (“tolerance”) 
to subsequent immune challenge. Previous work in both mice and humans demonstrated 
that infection with malaria can both serve as a priming stimulus and promote tolerance to 
subsequent infection. In this study, we demonstrate that initial stimulation with 
Plasmodium falciparum iRBCs or the malaria crystal Hz induced human adherent 
PBMCs to hyperrespond to subsequent stimulation of TLR receptors. This 
hyperresponsiveness correlated with increased H3K4me3 at important immunometabolic 
promoters, and these epigenetic modifications were also seen in Kenyan children 
naturally infected with malaria.  However, the use of epigenetic and metabolic inhibitors 
indicated that the induction of trained immunity by malaria and its ligands may occur via 
previously unrecognized mechanism(s).  
		
	
	
	
57	
Introduction 
A hallmark of malaria is robust proinflammatory cytokine production induced by 
widespread innate immune activation. Multiple innate immune receptors are involved in 
the recognition of Plasmodium iRBCs and other malarial ligands [reviewed in (133)]. For 
example, the malaria crystal Hz, which becomes coated with Plasmodium-derived 
PAMPs including genomic DNA as a result of parasite turnover, activates TLR9 in the 
phagolysosome (49). These Hz crystals can also induce phagolysosomal rupture resulting 
in the activation of the nucleotide-binding domain, leucine-rich repeat-containing, pyrin 
domain containing 3 (NLRP3) inflammasome as well as deliver Plasmodium DNA to the 
cytosol, where it is recognized by the AIM2 inflammasome and a cytosolic DNA receptor 
that senses AT-rich stem-loop structures in Plasmodium genomes (53, 55). This innate 
immune response, although beneficial through limiting parasitemia and assisting in the 
activation of adaptive immunity (56), induces the systemic symptoms of fever, nausea, 
and malaise.  Additionally, proinflammatory cytokinemia has been implicated in the 
development of cerebral malaria (57).  
Multiple studies over the past decade have demonstrated memory phenotypes in 
innate immune cells (95, 96, 100). In the prevailing model of innate immune memory, an 
initial stimulus primes the innate immune system, which, depending on the type and 
concentration of the stimulus, induces epigenetic and metabolic changes that result in an 
increased or decreased response—termed training and tolerance, respectively—to a 
subsequent challenge occurring days to months after the priming challenge (150). 
Malarial infection serves as a robust priming stimulus, as whole blood samples from 
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experimentally infected individuals and PBMCs from naturally infected individuals with 
acute febrile disease are hyperresponsive to ex vivo TLR ligand stimulation—a phenotype 
that can be recapitulated by stimulating naïve donor PBMCs with iRBC extract in vitro 
(106, 107).  
Malarial infection can induce tolerance to subsequent malaria infection or other 
immune challenge [reviewed in (110)]. A reanalysis of experimental P. falciparum 
infection data demonstrated that the pyrogenic threshold—the level of parasitemia 
required to provoke fever—was higher for individuals after reinfection compared to 
initial infection (151). In an area of Mali with malaria transmission only during the rainy 
season, nearly 50% of healthy asymptomatic individuals had detectable parasitemia at the 
end of the dry season (152). Individuals infected with malaria as fever therapy for 
neurosyphilis and then challenged 2-3 days post final defervescence with heat-killed 
Salmonella exhibited depressed febrile responses (115). Interestingly, tolerance and 
training appear to be two ends of the same spectrum, as LPS and other ligands induce 
tolerance at higher concentrations but produce training at much lower concentrations 
(105). Therefore, we hypothesized that malarial stimulation would also induce trained 
immunity and set about to evaluate this possibility directly using human PBMCs.  
		
	
	
	
59	
Results 
Primary stimulation of leukopak adherent PBMCs with malaria parasites or ligands 
induces increased proinflammatory cytokine production in response to secondary TLR 
stimulation 
Adherent PBMCs were generated from leukopaks (leukapheresis product with 
concentrated PBMCs) by isolating PBMCs via density gradient centrifugation and 
allowing the PBMCs to adhere to tissue-culture treated polystyrene plates for ³ 1 hour. 
After washing the plates 3x with warm PBS to remove non-adherent cells, the adherent 
PBMCs were stimulated with media containing 10% human serum (RPMI+) alone, 
Plasmodium falciparum iRBCs, uninfected red blood cells (uRBCs) or Hz for 24 hours. 
The cells were then washed and allowed to rest in RPMI+ for three days or five days. At 
this point, the cells were stimulated with the TLR2 ligand Pam3CSK4 or the TLR4 ligand 
LPS for 24 hours, at which point the supernatants were removed and TNFa and IL-6  
levels were measured by ELISA. Since different training stimuli seemed to consistently 
induce higher or lower levels of adherent PBMCs by the end of the experiment (data not 
shown), we controlled for cell number by performing an MTS assay on the cells after 
removing the supernatants, and we normalized the cytokine values to relative cell 
numbers determined by the MTS assay. Training with either 1x105 or 1x106 iRBCs—but 
not similar quantities of uRBCs—and allowing the cells to rest for three or five days 
induced increased production of TNFa after a 24 h second stimulation with Pam3CSK4 
as compared to control (RPMI+) trained cells (Fig. 4.1A). Although the differences in 
TNFa production over control-trained cells appeared to be greater after iRBC primary 
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stimulation and three days of rest than after iRBC stimulation and five days of rest, 
iRBC-induced training was only significant after the five-day rest. Similarly, primary 
stimulation with Hz induced increased production of TNFa in a dose-dependent manner 
following three or five days of rest and Pam3CSK4 restimulation; however, these 
differences were significantly greater than control only when training with 10 µM of Hz 
paired with three-day rest or 100 µM of Hz paired with five-day rest (Fig. 4.1A). Only 
training with the lower concentration of iRBC before either duration of rest induced 
increased IL-6 post-Pam3CSK4 stimulation, and this training effect was only significant 
after three days’ rest (Fig. 4.1B). As seen with TNFa, training with Hz induced increased 
production of IL-6 in a largely dose-dependent manner after TLR2 challenge. This Hz-
induced training was significant for the 100 and 10 µM Hz doses after three days’ rest 
and for the 10 µM Hz dose after 5 days’ rest. (Fig 4.1B). 
 When LPS was given as the second stimulus, the training effects of iRBCs and Hz 
were not as robust. There were trends towards increased TNFa production after iRBC 
training, three-day rest, and LPS challenge, but these trends were not seen if LPS 
challenge came five days after iRBC training (Fig. 4.1C). Similarly, primary stimulation 
with any of the three concentrations of Hz had no effect on TNFa production as a result 
of LPS challenge. Training with iRBCs or higher concentrations of Hz increased IL-6 
production after three-day rest and LPS challenge, but this was only significant for 
training with 105 iRBCs, and no significant training was seen with a rest duration of 5 
days (Fig. 4.1D). Based on these results, we decided to use a three-day rest period for all 
future experiments. 
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Figure 4.1. Effect of pretreatment (“training”) with P. falciparum iRBCs or Hz three or 
five days before TLR ligand stimulation of human adherent PBMCs isolated from 
leukopaks. (A-D) TNFa (A, C) and IL-6 (B, D) ELISA measurements of supernatants 
from leukopak adherent PBMCs trained for 24 h with iRBCs, uRBCs, or Hz, rested for 3 
d or 5 d, then challenged with Pam3CSK4 (A, B) or LPS (C, D) for 24 h. Bars represent 
mean ± SEM for seven donors (all comparisons to RPMI+ trained for similar duration of 
rest, *p<0.05, **p<0.01, paired t-test). 
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Induction of trained innate immunity by Plasmodium falciparum appears to be lost in a 
purer monocyte population 
For the experiments described in Figure 4.1, we utilized adherent PBMCs, as this was the 
cell population used in earlier descriptions of trained immunity (95, 96). Examination of 
these populations via light microscopy showed a heterogeneous mix of cells; therefore, 
we decided to repeat some of the experiments shown in Figure 4.1 in a purer monocyte 
population. For these experiments, we again isolated PBMCs from leukopaks. For each 
leukopak, some of the PBMCs were allowed to adhere to polystyrene dishes as described 
above to produce adherent PBMCs, while the rest of the leukopak PBMCs underwent 
monocyte enrichment via negative selection using the EasySep Human Monocyte 
Enrichment Kit without CD16 depletion (STEMCELL Technologies). The training assay 
was then performed as described above with a three-day rest.  
 In general, the results for the adherent PBMCs look quite similar to those in 
Figure 4.1. Training with iRBCs and Hz resulted in increased TNFa production after 
secondary Pam3CSK4 stimulation, but this increased TNFa production was not 
significant for any training stimulus (Fig. 4.2A), presumably because of the relatively 
small sample size of three individual donors. Interestingly, increased TNFa after iRBC or 
Hz pretreatment was not seen in the negatively selected monocytes (Fig 4.2A). This 
difference in training between adherent PBMCs and monocytes was seen regardless of 
the training stimulus or challenge stimulus. For example, training with 105 iRBCs 
appeared to induce increased IL-6 after Pam3CSK4 second stimulus in adherent PBMCs, 
but this training effect was not seen in monocytes (Fig 4.2B). After primary stimulation 
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with 106 iRBCs and LPS challenge, negatively selected monocytes actually produced 
decreased levels of IL-6 as compared to media-trained, LPS-challenged monocytes (Fig. 
2D). Although the small sample size precludes the making of any robust conclusions, 
these data suggest that P. falciparum-induced training is not seen in negatively selected 
monocytes.  
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Figure 4.2. Comparison of P. falciparum innate immune memory assay in adherent 
PBMCs and monocytes. (A-D) TNFa (A, C) and IL-6 (B, D) ELISA measurements of 
supernatants from leukopak adherent PBMCs or negatively-selected monocytes trained 
for 24 h with iRBCs, uRBCs, or Hz, rested for 3 d, and then challenged with Pam3CSK4 
(A, B) or LPS (C, D) for 24 h. Bars represent mean ± SEM for three donors (all 
comparisons to RPMI+ trained for similar cell populations, *p<0.05, **p<0.01, paired t-
test). 
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Training with P. falciparum iRBCs and Hz induces increased proinflammatory cytokine 
production after Pam3CSK4 challenge in adherent PBMCs drawn from the same donor 
on different days 
For the previous experiments, we used adherent PBMCs or monocytes from leukopaks 
because leukopaks were a relatively cheap and easy source for large numbers of PBMCs. 
However, the interdonor variability was quite large. Although a recent paper 
demonstrated the extent of interdonor variability in PBMC responses to common 
pathogens and TLR ligands, including Pam3CSK4 and LPS (153), we wondered if some 
of the variability in our assay could be due to the fact that our leukopaks came from out-
of-state and were shipped overnight at ambient temperatures. In an attempt to minimize 
this variability, we performed our trained immunity assay on adherent PBMCs taken 
from the same donor on eight different days over the course of roughly thirteen months. 
Significant increases in both TNFa (Fig. 4.4A) and IL-6 (Fig 4.4B) post-Pam3CSK4 
challenge were seen in adherent PBMCs trained with either iRBCs or Hz. Training with 
malaria ligands had no effect on TNFa production (Fig. 4.4C) and mild effects on IL-6 
production (Fig. 4.4D) post-LPS challenge.   
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Figure 4.3. P. falciparum iRBCs and Hz induce trained immunity in adherent PBMCs 
from a single donor. (A-D) TNFa (A, C) and IL-6 (B, D) ELISA measurements of 
supernatants from adherent PBMCs trained for 24 h with iRBCs, uRBCs, or Hz, rested 
for 3 d, and then challenged with Pam3CSK4 (A, B) or LPS (C, D) for 24 h. Bars 
represent mean ± SEM for eight (RBCs) or seven (Hz) experiments using adherent 
PBMCs drawn from the same donor on different days (all comparisons to RPMI+ trained 
cells, *p<0.05, **p<0.01, paired t-test). 
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Training freshly-drawn adherent PBMCs with malaria parasites or Hz induces increased 
proinflammatory and decreased anti-inflammatory cytokine production in response to 
Pam3CSK4 challenge 
Given the reproducibility of malaria-induced training in adherent PBMCs drawn from the 
same donor on different days, we decided to expand perform our trained immunity assay 
on adherent PBMCs taken from additional healthy donors. Training with either 1x105 or 
1x106 iRBCs induced increased production of both TNFa and IL-6 24 h after secondary 
stimulation with Pam3CSK4. Similarly, primary stimulation with 100 µM or 10 µM Hz 
also induced increased production of these proinflammatory (Fig. 4.4A, B). However, 
training with malarial ligands had little effect on either TNFa and IL-6 production post-
LPS secondary stimulation (Fig. 4.4C, D). Conversely, training with iRBCs significantly 
decreased production of the anti-inflammatory cytokine IL-10 after Pam3CSK4 challenge 
(Fig. 4.5A). Decreased IL-10 production was also seen after iRBC training/LPS 
challenge, Hz training/Pam3CSK4 challenge, and Hz training/LPS challenge, but these 
decreases were not significant (Fig. 4.5A, B). 
 
		
	
	
	
68	
 
Figure 4.4. P. falciparum iRBCs and Hz induce increased proinflammatory cytokine 
production post-Pam3CSK4 challenge. (A-D) TNFa (A, C) and IL-6 (B, D) ELISA 
measurements of supernatants from freshly-drawn adherent PBMCs trained for 24 h with 
iRBCs, uRBCs, or Hz, rested for 3 d, and then challenged with Pam3CSK4 (A, B) or LPS 
(C, D) for 24 h. Bars represent mean ± SEM for eight donors (all comparisons to RPMI+ 
trained, *p<0.05, **p<0.01, ***p<0.001, paired t-test). 
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Figure 4.5. P. falciparum iRBCs and Hz induce decreased IL-10 production post TLR 
challenge. (A, B) IL-10 ELISA measurements of supernatants from freshly-drawn 
adherent PBMCs trained for 24 h with iRBCs, uRBCs, or Hz, rested for 3 d, and then 
challenged with Pam3CSK4 (A) or LPS (B) for 24 h. Bars represent mean ± SEM for 
three donors (all comparisons to RPMI+ trained, *p<0.05, paired t-test). 
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Malarial training has wide-ranging effects on the inflammatory transcriptome post-TLR 
second stimulus 
The prevailing model of trained immunity is that increased responsiveness to secondary 
stimuli results from epigenetic remodeling that increases chromatin accessibility. It 
follows that increased proinflammatory gene transcription should follow secondary 
stimulation. In our in vitro model, stimulation of iRBC- or Hz-trained—but not uRBC-
trained—adherent PBMCs with Pam3CSK4 for either 4 or 12 hrs increased transcription 
at the TNF locus as compared to cells trained with media alone (Fig. 4.6A). Interestingly, 
malarial training did not lead to increased IL6 transcription after 4 h Pam3CSK4 second 
stimulation, but there was a trend towards increased IL6 transcription in iRBC- and Hz-
trained cells after 12 h Pam3CSK4 stimulation (Fig. 4.6B). To determine if malarial 
training has a more global effect on inflammatory gene expression, we performed a 
NanoString analysis on RNA harvested from malaria-trained cells given Pam3CSK4 as a 
secondary stimulus for 4 or 12 hrs. For each of the roughly 250 genes analyzed, we 
normalized the iRBC-, uRBC-, or Hz-trained transcript count to the control-trained 
transcript count at each secondary stimulus time point. These normalized ratios were 
log(2) transformed and displayed as a heatmap (Fig. 4.6C), which demonstrated that 
while uRBC training had little effect on the inflammatory transcriptome, both iRBC and 
Hz training had wide-ranging and similar effects. Based on hierarchical clustering, the 
majority of transcripts can be broadly classified into the following cohorts: globally 
upregulated (C1), upregulated after 4 h Pam3CSK4 stimulation (C2), upregulated after 12 
h Pam3CSK4 stimulation (C3), downregulated after 12 h Pam3CSK4 stimulation (C4), 
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downregulated after 4 h Pam3CSK4 stimulation (C5), or globally downregulated (C6). 
Individual genes from each cohort previously implicated in malarial pathogenesis and/or 
trained immunity are listed in parenthesis after the cohort number (154-158). The 
normalized ratios for each gene found in the same order as in Figure 4.6C can be found in 
Table 4.1.  
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Figure 4.6. Malaria-induced training has wide-range effects on the transcriptional 
response to subsequent challenge. (A, B) mRNA was harvested from adherent PBMCs 
trained with iRBCs or Hz, rested for 3 d, and challenged with Pam3CSK4 for 4 or 12 h. 
Expression levels of TNF (A) and IL6 (B) relative to RPMI+ trained cells are shown. 
Bars represent mean ± SEM for eight (4 h Pam3CSK4) or three (12 h Pam3CSK4) 
donors (**p<0.01, paired t-test). (C) Gene expression from cells treated as in (A) and (B) 
was quantified using NanoString technology. Expression counts were represented as log2 
fold change compared to control-trained cells and plotted using hierarchical clustering. 
Each row represents one gene. Values shown are the means of two independent 
experiments from one of the donors in (A) and (B).   
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GENE	
NAME	
URBCS,	
PAM	4H	
URBCS,	
PAM	12H	
IRBCS,	
PAM	4H	
IRBCS,	
PAM	12H	
HZ,	PAM	
4H	
HZ,	PAM	
12H	
IL5	 2.92	 0.02	 7.15	 5.74	 5.66	 4.10	
IL13	 1.48	 0.08	 4.43	 3.83	 2.60	 2.69	
CCL4	 0.41	 0.02	 1.45	 1.71	 1.54	 1.01	
TNFSF1
4	
0.09	 -0.37	 1.74	 1.56	 1.84	 1.02	
CXCL9	 1.93	 1.84	 5.93	 6.42	 4.55	 4.56	
TNF	 0.83	 0.14	 2.57	 3.57	 1.97	 1.99	
CCL19	 0.44	 1.27	 3.98	 3.57	 2.56	 2.40	
IL21	 0.27	 0.16	 4.08	 2.90	 2.16	 2.28	
IL23R	 1.04	 -0.08	 1.96	 2.24	 1.22	 0.56	
C1R	 -0.84	 2.23	 5.29	 4.79	 4.93	 3.93	
CRP	 -0.62	 0.42	 0.99	 1.24	 0.90	 0.55	
PTGIR	 0.10	 0.37	 0.79	 0.93	 1.14	 0.83	
C7	 -2.33	 -0.51	 -0.26	 0.83	 0.76	 0.35	
C7	 -2.33	 -0.51	 -0.26	 0.83	 0.76	 0.35	
IFNG	 0.87	 1.67	 3.81	 4.57	 2.24	 3.41	
JUN	 -0.21	 0.17	 0.33	 0.74	 0.12	 0.61	
CCR4	 0.07	 0.53	 1.08	 2.57	 0.24	 1.15	
AREG	 -0.06	 0.44	 2.53	 4.22	 2.46	 3.66	
FLT1	 -0.03	 -0.23	 1.91	 2.52	 1.47	 2.34	
CCL3	 0.30	 0.09	 1.34	 1.98	 1.38	 1.62	
FXYD2	 -0.48	 -0.85	 0.28	 1.22	 0.37	 0.82	
C8B	 -0.26	 0.38	 1.49	 3.22	 1.89	 1.95	
IL23A	 -0.31	 -0.05	 0.97	 3.11	 1.13	 2.47	
CXCL2	 0.16	 -0.54	 1.71	 2.68	 2.27	 2.84	
IL8	 -0.12	 -0.37	 0.35	 0.81	 0.87	 0.99	
IL6	 -0.07	 -0.05	 0.67	 1.61	 1.23	 2.12	
IL9	 0.01	 0.15	 2.65	 2.56	 2.00	 2.97	
MBL2	 -1.05	 -0.53	 1.17	 1.23	 0.90	 1.98	
IL11	 0.50	 0.55	 0.61	 1.45	 1.92	 2.00	
CXCL3	 0.01	 -0.33	 0.50	 0.89	 1.29	 1.68	
LTB4R	 -0.05	 -0.29	 0.04	 0.30	 0.36	 0.57	
CCL20	 -0.39	 -0.66	 -0.37	 0.32	 0.42	 0.74	
ALOX12	 -0.83	 -0.47	 0.19	 0.50	 1.12	 2.09	
C2	 0.00	 -0.12	 2.37	 1.77	 2.46	 1.91	
MAFF	 -0.23	 -0.21	 1.23	 1.05	 1.27	 0.93	
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CFB	 -0.78	 -0.45	 2.11	 1.64	 1.97	 1.88	
HLA−DR
B1	
0.24	 0.27	 1.13	 1.34	 1.55	 1.46	
HLA−DR
A	
0.25	 0.19	 1.19	 1.15	 1.60	 1.42	
IL18	 -0.17	 -0.21	 0.49	 0.37	 0.60	 0.69	
NLRP3	 0.22	 -0.41	 0.76	 0.78	 1.00	 1.29	
RIPK2	 0.23	 -0.23	 0.71	 0.61	 0.79	 0.85	
PTGER1	 0.37	 -0.02	 0.94	 1.00	 1.13	 1.03	
IL1RN	 0.02	 -0.34	 1.06	 0.86	 0.74	 1.15	
IL3	 1.19	 0.24	 3.60	 1.93	 2.40	 2.77	
IFNA1	 1.76	 -0.66	 3.28	 0.66	 2.74	 2.32	
PTGFR	 0.74	 -1.03	 0.61	 0.32	 -0.11	 1.00	
C1S	 1.26	 0.67	 6.50	 4.48	 5.77	 3.68	
IL2	 -0.24	 1.20	 4.48	 2.89	 4.32	 2.27	
CSF1	 0.18	 0.33	 2.35	 1.08	 2.22	 1.01	
CCL21	 1.36	 1.00	 3.25	 1.95	 3.46	 1.53	
ITGB2	 0.09	 0.09	 0.92	 0.40	 0.96	 0.27	
C1QA	 0.36	 0.24	 2.36	 0.70	 2.48	 0.41	
MMP9	 0.81	 0.02	 2.94	 1.28	 2.50	 0.72	
LIMK1	 0.06	 -0.24	 1.47	 0.51	 1.35	 0.70	
FOS	 -0.09	 -0.74	 0.95	 0.28	 1.16	 0.27	
CEBPB	 -0.14	 -0.37	 0.44	 -0.03	 0.70	 0.32	
CCR1	 -0.31	 -0.11	 0.82	 0.08	 1.18	 0.29	
MRC1	 0.39	 -0.28	 2.32	 -0.16	 2.22	 0.37	
C1QB	 0.06	 0.17	 1.36	 -0.10	 1.47	 0.14	
CCL24	 0.91	 -0.11	 2.78	 -0.90	 2.92	 -0.04	
TLR2	 0.24	 -0.08	 0.62	 -0.17	 1.27	 0.15	
CCL8	 0.82	 2.43	 3.43	 1.48	 3.23	 1.56	
CCL13	 0.04	 1.30	 4.11	 -0.91	 4.95	 -1.49	
IL17A	 0.01	 1.03	 3.51	 1.61	 2.39	 1.05	
TLR8	 -0.18	 0.32	 1.78	 0.52	 1.34	 0.62	
KNG1	 0.01	 -0.14	 2.63	 0.03	 1.16	 0.52	
CXCL5	 0.59	 -0.45	 0.75	 -0.80	 1.65	 1.00	
IL1A	 0.34	 -0.34	 0.16	 -0.96	 1.20	 0.44	
PTGS1	 0.38	 -0.14	 0.83	 -0.56	 1.17	 0.54	
C3AR1	 0.03	 0.06	 0.33	 -0.38	 0.80	 0.32	
CFD	 0.26	 -0.11	 0.07	 -0.37	 1.03	 1.18	
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C3	 -0.24	 -0.38	 -0.14	 -0.72	 0.77	 0.52	
IL1B	 0.03	 -0.25	 0.01	 -0.06	 0.74	 0.68	
CCL11	 -2.18	 -1.10	 0.01	 -1.67	 -0.58	 0.85	
IL22RA2	 0.67	 1.36	 1.18	 1.68	 3.19	 0.55	
PIK3C2G	 0.01	 0.15	 0.03	 1.74	 1.63	 0.55	
MASP1	 0.01	 -0.54	 0.03	 0.88	 2.72	 0.88	
MYL2	 0.01	 1.03	 0.03	 0.33	 1.22	 0.55	
CSF2	 0.34	 0.08	 1.16	 3.80	 1.91	 3.56	
PTGS2	 -0.19	 -0.57	 0.40	 2.21	 0.85	 2.45	
IL1R1	 0.18	 -0.67	 0.06	 2.35	 0.84	 2.28	
CCL16	 -0.40	 -1.13	 0.00	 1.34	 0.37	 1.53	
CSF3	 -0.79	 -1.00	 -0.69	 2.67	 1.02	 3.16	
MMP3	 -0.50	 -0.62	 -0.54	 1.66	 0.60	 2.52	
MAP2K
1	
0.03	 0.01	 0.07	 0.39	 0.09	 0.50	
MAPKA
PK2	
0.10	 -0.01	 -0.06	 0.62	 0.17	 0.28	
IL12B	 1.35	 1.75	 1.09	 2.45	 1.40	 2.25	
TNFAIP3	 0.00	 -0.02	 -0.16	 0.22	 -0.02	 0.18	
MAFK	 -0.22	 0.04	 -0.40	 0.63	 0.12	 0.54	
IL15	 0.08	 0.28	 0.03	 0.73	 0.24	 0.94	
IL6R	 -0.23	 0.10	 -0.21	 0.75	 0.26	 0.90	
RAPGEF
2	
0.11	 0.12	 -0.11	 0.34	 0.14	 0.48	
NOS2	 -0.33	 2.08	 0.03	 3.22	 2.12	 3.13	
C8A	 0.01	 0.15	 0.03	 0.33	 0.33	 0.55	
C6	 -0.82	 0.46	 0.70	 1.00	 0.68	 1.55	
GNGT1	 -0.96	 -0.18	 -0.23	 0.72	 0.11	 0.84	
C9	 -0.12	 2.26	 0.03	 3.17	 0.44	 2.60	
OASL	 -0.30	 0.92	 -0.54	 2.01	 -0.39	 1.51	
TBXA2R	 -0.30	 0.87	 0.11	 1.79	 0.36	 0.90	
BCL2L1	 0.37	 0.20	 -0.15	 0.70	 -0.15	 0.67	
TGFB1	 0.20	 0.04	 -0.14	 0.58	 -0.08	 0.65	
CD86	 -0.19	 -0.19	 -0.40	 -0.15	 -0.46	 0.53	
TSLP	 0.13	 -0.14	 -2.48	 1.58	 1.16	 1.94	
CXCR1	 -0.53	 -0.17	 -1.35	 0.57	 0.35	 0.60	
MAFG	 -0.06	 -0.13	 -0.36	 -0.08	 0.14	 0.21	
GNAQ	 -0.25	 -0.06	 -0.86	 -0.50	 -0.55	 0.02	
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ATF2	 -0.04	 0.11	 -0.39	 0.04	 -0.07	 0.28	
IFNB1	 -0.69	 0.02	 -1.63	 -0.30	 -0.56	 0.21	
ELK1	 0.06	 -0.09	 -0.48	 -0.04	 -0.02	 0.11	
IL10RB	 -0.25	 -0.20	 -0.89	 -0.40	 -0.32	 -0.08	
NFE2L2	 -0.05	 0.08	 -0.57	 -0.19	 -0.12	 -0.09	
TLR5	 -0.73	 0.02	 -3.86	 -1.09	 -1.93	 -0.43	
ALOX15	 0.67	 0.21	 0.03	 0.16	 0.33	 0.38	
SMAD7	 0.15	 -0.18	 -0.27	 -0.21	 0.14	 -0.12	
CXCL1	 0.23	 -0.27	 -0.51	 -0.78	 0.38	 0.38	
TOLLIP	 -0.12	 -0.06	 -0.47	 -0.43	 -0.18	 0.16	
RAC1	 -0.20	 -0.14	 -0.55	 -0.40	 -0.17	 -0.01	
PLA2G4
A	
-0.32	 -0.15	 -0.88	 -1.13	 -0.20	 -0.11	
PTGER2	 -0.11	 -0.42	 -1.14	 -1.03	 -0.37	 -0.14	
HIF1A	 -0.04	 -0.16	 -0.93	 -0.89	 -0.32	 0.14	
TLR4	 -0.28	 -0.34	 -1.51	 -1.60	 -0.74	 -0.16	
IFIT2	 0.15	 0.97	 0.68	 0.13	 0.22	 0.45	
OXER1	 1.77	 0.59	 1.84	 -0.87	 1.92	 -2.14	
HSH2D	 0.13	 0.72	 0.26	 -0.05	 -0.13	 -0.76	
CD4	 0.04	 0.33	 -0.27	 -0.27	 -0.02	 -1.22	
IL1RAP	 0.44	 -0.13	 0.35	 -1.06	 0.30	 0.09	
ALOX5	 -0.04	 0.34	 0.47	 -0.71	 0.57	 -0.04	
LY96	 -0.06	 -0.07	 0.02	 -0.99	 0.35	 -0.30	
CCL2	 0.19	 -0.16	 -0.27	 -3.73	 0.71	 -1.79	
CD163	 0.40	 0.55	 -0.46	 -1.12	 0.74	 -0.11	
TYROBP	 0.00	 -0.06	 -0.71	 -0.90	 0.16	 -0.28	
PTGDR2	 1.10	 1.02	 -0.52	 -0.43	 1.68	 -1.39	
HSPB1	 -0.30	 -0.06	 -0.36	 -1.16	 -0.03	 -0.95	
NOX1	 -0.60	 0.23	 -0.86	 -1.76	 0.92	 -1.44	
STAT1	 0.66	 1.09	 0.17	 -0.36	 0.14	 -0.03	
NOD1	 0.30	 0.31	 0.01	 -0.72	 -0.17	 -0.27	
PLCB1	 -0.16	 0.05	 -1.10	 -1.90	 -0.75	 -1.07	
TREM2	 0.04	 0.08	 -1.32	 -2.46	 -0.37	 -1.51	
CXCL6	 1.45	 0.17	 -0.18	 -3.04	 0.80	 -1.73	
CCL7	 0.33	 0.20	 -0.53	 -3.00	 -0.05	 -1.90	
CFL1	 0.19	 0.15	 -0.06	 -0.29	 0.14	 -0.28	
CYSLTR2	 0.19	 0.40	 -0.55	 -1.28	 0.00	 -1.70	
CCL23	 0.25	 0.39	 -0.49	 -0.86	 -0.14	 -0.82	
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MAPK3	 0.14	 0.37	 -0.58	 -1.39	 -0.25	 -1.30	
CXCR4	 0.06	 0.15	 -0.37	 -1.04	 -0.48	 -0.94	
CD55	 -0.15	 0.07	 -0.67	 -1.51	 -0.80	 -1.70	
IL4	 3.82	 3.41	 4.72	 3.79	 3.40	 1.79	
CCL17	 1.84	 0.55	 3.52	 2.33	 1.09	 -0.90	
CXCL10	 1.88	 2.21	 3.06	 2.78	 1.86	 2.17	
CCL22	 0.89	 0.52	 1.61	 1.98	 -0.15	 0.32	
FASLG	 0.66	 0.45	 0.34	 0.57	 0.05	 -0.42	
CD40	 0.41	 0.26	 0.32	 0.20	 -0.13	 -0.06	
MAP3K
9	
1.01	 0.16	 -0.40	 -0.30	 -1.14	 -0.94	
ARG1	 1.05	 -1.04	 -0.24	 1.01	 -0.52	 -0.40	
IFIT1	 0.14	 2.25	 0.22	 1.61	 -0.09	 1.42	
IRF7	 -0.05	 0.66	 -0.19	 0.41	 -0.20	 0.30	
OAS2	 0.04	 0.98	 0.13	 0.87	 -0.25	 0.29	
C4A	 0.67	 1.95	 1.21	 1.31	 -0.25	 1.15	
CCR2	 0.69	 1.27	 0.25	 1.88	 -0.10	 0.55	
HMGB2	 -0.78	 0.15	 -1.23	 0.50	 -1.32	 -0.57	
LTA	 0.17	 0.41	 0.12	 0.75	 -0.32	 0.03	
TLR7	 0.06	 0.48	 -0.25	 0.76	 0.01	 -0.31	
CXCR2	 -0.63	 1.01	 -2.44	 -0.18	 -1.07	 -1.56	
IFIT3	 -0.14	 1.26	 0.42	 0.71	 0.15	 0.97	
TWIST2	 -0.73	 1.69	 -0.25	 0.33	 -0.07	 0.55	
IFI44	 0.02	 1.15	 0.16	 0.23	 0.05	 0.43	
MX1	 -0.46	 0.97	 -0.40	 0.05	 -0.66	 -0.06	
MASP2	 -0.39	 0.80	 -0.36	 0.33	 -0.07	 0.55	
HSPB2	 -1.00	 1.30	 -1.26	 1.08	 -0.56	 0.64	
IRF1	 0.55	 0.80	 -0.11	 0.23	 -0.55	 0.24	
MEF2D	 0.30	 0.47	 -0.31	 0.13	 -0.99	 0.09	
CCR3	 3.95	 3.65	 1.91	 3.26	 2.41	 2.82	
MAPK8	 0.08	 0.02	 -0.53	 -0.24	 -0.33	 -0.07	
IL10	 0.42	 0.47	 -2.23	 -0.20	 -1.07	 -0.17	
DDIT3	 -0.08	 0.04	 -1.42	 -0.57	 -0.88	 -0.45	
TLR1	 0.20	 0.05	 -0.96	 -0.14	 -0.74	 0.07	
ROCK2	 0.08	 -0.09	 -0.71	 -0.31	 -0.77	 -0.17	
SHC1	 0.02	 0.22	 -0.72	 -0.31	 -0.55	 -0.10	
BCL6	 -0.09	 0.12	 -1.12	 -0.56	 -0.87	 -0.16	
TLR6	 0.09	 0.41	 -1.26	 -0.35	 -1.16	 0.04	
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RAF1	 0.05	 0.10	 -0.85	 -0.42	 -0.80	 -0.17	
MAPK1
4	
0.02	 0.13	 -1.75	 -0.69	 -1.65	 -0.32	
NFATC3	 0.04	 0.28	 -1.65	 -0.87	 -1.59	 -0.81	
MYD88	 0.08	 0.33	 -0.90	 -0.41	 -0.68	 -0.30	
TRADD	 0.05	 0.35	 -1.71	 -0.81	 -1.16	 -0.52	
CREB1	 -0.04	 0.19	 -1.99	 -1.10	 -1.50	 -0.75	
NOD2	 -0.08	 0.33	 -0.66	 0.39	 -1.10	 0.31	
PRKCB	 -0.16	 0.10	 -0.95	 0.18	 -0.90	 0.15	
PDGFA	 -0.13	 0.67	 -1.50	 0.78	 -1.09	 0.15	
C5	 -0.96	 1.25	 -4.11	 0.61	 -2.17	 -0.74	
MEF2A	 -0.16	 0.00	 -0.77	 -0.12	 -0.60	 -0.20	
TGFB2	 -0.47	 0.82	 -2.39	 0.01	 -1.80	 0.04	
MEF2B
NB−ME
F2B	
-1.81	 -0.61	 -3.49	 -1.56	 -2.92	 -1.33	
CCL5	 0.17	 0.54	 -0.81	 -0.23	 -1.05	 -1.06	
CD40LG	 0.00	 0.20	 -1.19	 -0.82	 -1.59	 -1.55	
IL18RAP	 0.70	 0.90	 -0.98	 0.33	 -0.95	 -0.67	
MAP2K
6	
-0.46	 0.60	 -3.06	 -1.39	 -2.77	 -3.05	
TCF4	 0.02	 0.39	 -1.92	 -0.97	 -1.36	 -1.28	
CCR7	 0.00	 0.42	 -1.93	 -1.18	 -1.84	 -1.46	
PTGER4	 0.00	 0.43	 -0.95	 -0.67	 -0.62	 -0.79	
CYSLTR1	 -0.14	 0.37	 -1.55	 -1.31	 -1.40	 -1.45	
DEFA1	 0.54	 1.06	 -2.50	 -1.82	 -2.04	 -1.76	
MYC	 -0.30	 0.33	 -2.66	 -1.90	 -2.20	 -2.10	
HMGB1	 0.05	 0.19	 -0.45	 -0.61	 -0.68	 -0.67	
RPS6KA
5	
0.17	 0.17	 -0.95	 -1.12	 -0.97	 -1.23	
STAT3	 0.07	 0.29	 -0.42	 -0.42	 -0.52	 -0.30	
MX2	 -0.21	 0.71	 -0.97	 -1.14	 -0.98	 -0.91	
TLR9	 -0.07	 0.81	 -1.12	 -1.30	 -1.33	 -1.25	
HDAC4	 0.12	 0.42	 -1.05	 -1.14	 -1.06	 -0.77	
PRKCA	 0.33	 0.59	 -1.93	 -2.33	 -1.94	 -1.68	
MEF2C	 0.29	 0.84	 -1.40	 -1.19	 -0.95	 -1.04	
IRF3	 0.18	 0.39	 -1.38	 -1.15	 -0.99	 -0.92	
HMGN1	 -0.12	 0.08	 -1.46	 -1.33	 -1.19	 -1.13	
PTGER3	 1.09	 1.65	 0.02	 0.34	 -0.26	 0.68	
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IL7	 0.25	 0.72	 -0.66	 -0.55	 -0.93	 0.07	
RELA	 0.05	 0.35	 -0.39	 -0.21	 -0.33	 -0.09	
STAT2	 0.26	 0.51	 -0.21	 -0.18	 -0.13	 0.22	
MAP3K
5	
0.09	 0.30	 -1.10	 -0.64	 -0.73	 -0.30	
TGFBR1	 -0.05	 0.11	 -0.95	 -0.71	 -0.62	 -0.26	
NFKB1	 0.15	 0.05	 -0.66	 -0.45	 -0.34	 -0.19	
NR3C1	 0.01	 0.04	 -0.88	 -0.46	 -0.31	 -0.25	
CDC42	 0.06	 0.03	 -0.38	 -0.24	 -0.11	 -0.15	
GRB2	 0.26	 0.42	 -0.97	 -0.53	 -0.26	 -0.22	
GNB1	 0.12	 0.10	 -0.68	 -0.90	 -0.41	 -0.40	
MKNK1	 0.00	 -0.10	 -1.03	 -1.28	 -0.71	 -0.70	
RHOA	 0.08	 0.11	 -0.36	 -0.31	 -0.07	 -0.13	
TGFB3	 -0.40	 -0.17	 -1.72	 -1.67	 -1.11	 -1.04	
LTB4R2	 -0.29	 -0.03	 -1.96	 -1.94	 -1.31	 -1.21	
IL12A	 0.30	 0.67	 -2.20	 -1.38	 -0.93	 -1.75	
GNAS	 0.03	 0.23	 -1.00	 -0.89	 -0.49	 -0.71	
TLR3	 0.41	 0.46	 -1.45	 -1.59	 -0.43	 -1.21	
PTK2	 -0.16	 0.20	 -1.51	 -1.89	 -1.05	 -1.34	
LTB	 0.02	 0.48	 -2.23	 -2.65	 -1.74	 -2.47	
KEAP1	 0.14	 -0.04	 -0.50	 -0.68	 -0.57	 -0.39	
PPP1R1
2B	
0.26	 0.11	 -1.38	 -2.10	 -1.45	 -0.97	
HRAS	 0.36	 0.16	 -0.49	 -0.35	 -0.27	 -0.38	
DAXX	 0.24	 0.06	 -0.48	 -0.45	 -0.52	 -0.40	
IRF5	 0.17	 0.02	 -0.63	 -0.69	 -0.64	 -0.55	
MAPK1	 0.09	 -0.04	 -0.86	 -0.59	 -0.62	 -0.36	
MAP2K
4	
0.22	 0.06	 -1.50	 -1.00	 -1.22	 -0.56	
MAPKA
PK5	
0.12	 -0.01	 -1.48	 -1.25	 -1.34	 -0.82	
BIRC2	 -0.02	 -0.07	 -1.18	 -0.96	 -0.90	 -0.57	
MAP3K
7	
-0.05	 -0.02	 -1.23	 -0.92	 -1.03	 -0.59	
RELB	 0.02	 0.24	 -1.39	 -0.98	 -0.91	 -0.70	
RIPK1	 0.12	 0.26	 -0.83	 -0.67	 -0.73	 -0.37	
MAX	 0.29	 0.36	 -0.97	 -0.90	 -0.86	 -0.62	
AGER	 0.19	 0.37	 -1.71	 -1.46	 -1.39	 -1.06	
TRAF2	 0.11	 0.20	 -1.22	 -1.11	 -1.06	 -0.73	
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MAP3K
1	
-0.03	 0.30	 -2.65	 -2.36	 -2.25	 -1.53	
 
Table 4.1. Normalized ratios comparing the iRBC-, uRBC-, or Hz-trained NanoString 
transcript count to the control-trained transcript count. mRNA was harvested from 
adherent PBMCs trained with iRBCs or Hz, rested for 3 d, and challenged with 
Pam3CSK4 for 4 or 12 h. NanoString gene expression counts were represented as log2 
fold change compared to control-trained cells stimulated for the same duration with 
Pam3CSK4 and plotted using hierarchical clustering. Each row represents one gene. 
Shown are the means of two independent experiments from one of the donors in Figure 
4.6A and B.  
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Robust malarial training was not seen in the transdifferentiated BLaER1 or THP-1 
human cell lines 
We have demonstrated that training with malarial parasites and Hz can induce adherent 
PBMCs to respond in a more proinflammatory manner to secondary TLR stimulation; 
however, we have not yet delved into the mechanism by which malaria stimulation does 
this. Therefore, we sought to identify a cell line that also displayed training 
characteristics after stimulation with malaria parasites and Hz. If we were successful, we 
could then engineer genetic knockouts to elucidate what PRRs and downstream signaling 
cascades were required for this malarial training phenotype.  
 A recent study described transduction the Seraphina B cell lymphoma cell line 
with the macrophage lineage transcription factor C/EBPa under the control of the 
estrogen receptor dependent promoter. When cells of one of the transduced clones, 
BLaER1, were exposed to estrogen, they transdifferentiated into macrophage-like cells 
that expressed macrophage cell surface markers, expressed a transcriptome similar to 
primary macrophages, and became both phagocytic and post-mitotic (159). Veit 
Hornung’s group then demonstrated that these cells respond to LPS in a manner similar 
to human primary monocytes, including alternative activation of the NLRP3 
inflammasome without a traditional second signal. They then utilized CRISPR-Cas9 to 
generate many knockout BLaER1 cell lines to further explore the mechanism behind this 
alternative inflammasome activation pathway (124). 
 We acquired this BLaER1 cell line, and after transdifferentiating the cells into 
macrophages, we also saw robust proinflammatory cytokine production in response to 
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LPS stimulation (Fig. 4.7A). We then utilized transdifferentiated BLaER1 cells in our in 
vitro trained immunity assay. We found that training with 106 iRBCs induced the 
BLaER1 cells to produce significantly more TNFa (Fig 4.7B) and IL-6 (Fig 4.7C) post-
LPS challenge. However, these cells did not show similarly significant training post 
Pam3CSK4 challenge (Fig 4.7D), and the levels of TNFa and IL-6 produced post-
Pam3CSK4 stimulation were quite low. We tested other TLR2 ligands (peptidoglycan, 
Pam2CSK4, and MALP-2) with similar results (data not shown).  
Since malarial training in adherent human PBMCs is seen more robustly with 
Pam3CSK4 challenge than LPS challenge (Figs. 4.4, 4.5), we decided to test the THP-1 
human monocyte cell line. Training with P. falciparum iRBCs or Hz had no effect on 
proinflammatory cytokine production post TLR challenge (Fig. 4.8).  
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Figure 4.7. Transdifferentiated BLaER1 cells respond to LPS, but do not display robust 
malarial trained immunity. (A) BLaER1 cells prior to transdifferentiation (BLaER1 B 
cells), post-transdifferentiation (BLaER1 monocytes) and adherent PBMCs were 
stimulated with media or 200 ng/mL LPS overnight, and cytokine concentrations were 
measured in the supernatants by ELISA. Data points represent technical replicates for one 
transdifferentiation experiment or adherent PBMCs from one donor. (B-D) TNFa (B) 
and IL-6 (C, D) ELISA measurements of supernatants from transdifferentiated BLaER1 
cells trained with iRBCs or Hz, rested for 3 d, then challenged with LPS (B, C) or 
Pam3CSK4 (D) for 24 h. Bars represent pooled mean ± SEM from three or four 
independent experiments (all comparisons to RPMI+ trained, *p<0.05, paired t-test). 
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Figure 4.8. P. falciparum iRBCs and Hz do not induce trained immunity in THP-1 
human monocytes. (A, B) TNFa (A) and IL-6 (B) ELISA measurements of supernatants 
from PMA-differentiated THP-1 cells trained with iRBCs or Hz, rested for 3 d, then 
challenged with LPS or Pam3CSK4 for 24 h. Bars represent mean ± SD for duplicate 
stimulations of THP-1 cells from one experiment (all comparisons to RPMI+ trained and 
not significant, unpaired t-test). 
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P. falciparum-induced training seen in mouse BMDMs, while iRBCs induce tolerance in 
mouse peritoneal exudate cells 
In a further attempt to develop an in vitro model of malaria-induced trained immunity 
amenable to genetic manipulation, we performed our trained immunity assay on mouse 
BMDMs and non-thioglycollate-elicited peritoneal exudate cells (PECs). We did not use 
thioglycollate elicitation because, although it increases the yield of PECs/mouse, it also 
induces some non-specific activation of the cell and may partially inhibit phagocytosis 
(160). Training with iRBCs did not induce increased TNFa in mouse BMDMs post-LPS 
challenge, although TNFa was slightly increased after training with 100 µM 
Hz/Pam3CSK4 challenge (Fig. 4.9A). Training with 106 iRBCs did promote increased 
chemokine RANTES after both LPS and Pam3CSK4 challenge (Fig. 4.9B). Pretreatment 
with 2.4x106 PbA iRBCs for 36 hrs, followed by three-day rest, significantly decreased 
TNFa production after secondary stimulation with LPS or Pam3CSK4 (Fig. 4.9C), 
potentially indicating the induction of tolerance.  
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Figure 4.9. P. falciparum iRBCs and Hz induce innate immune memory in mouse 
BMDMs and PECs. (A, B) TNFa (A) and RANTES (B) ELISA measurements of 
supernatants from mouse BMDMs trained with iRBCs or Hz, rested for 3 d, then 
challenged with LPS or Pam3CSK4 for 24 h. Bars represent mean ± SD for technical 
quadruplicates from one experiment (all comparisons to RPMI+ trained, *p<0.05, 
**p<0.01, unpaired t-test) (C) TNFa ELISA measurements of supernatants from non-
thioglycollate-elicited mouse PECs stimulated with PbA iRBCs for 36 h, rested for 3 d, 
then challenged with LPS or Pam3CSK4 for 24 h. Bars represent mean ± SD for 
duplicate stimulations of cells from one experiment (all comparisons to RPMI+ trained, 
*p<0.05, unpaired t-test). 
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Adherent PBMCs contain multiple cell types and malaria-induced training alters the 
relative proportions of these cell types 
As mentioned earlier in this Chapter, training with malaria iRBCs and Hz consistently 
results in increased numbers of adherent PBMCs as compared to control-trained adherent 
PBMCs; therefore, we normalized the raw cytokine values to cell numbers estimated by 
the use of a MTS assay. In addition to increased adherent PBMC numbers, we also saw 
that the adherent PBMCs trained with malarial ligands were often larger and had more of 
an activated macrophage phenotype (Fig. 4.10A). To determine the both the composition 
of the adherent PBMCs and the contribution of adherence to changing the relative 
makeup of the PBMC population, we perform flow cytometry on freshly isolated PBMCs 
and the adherent PBMCs remaining after at least 1 h of adherence and three washes with 
PBS. To our great surprise, the two populations were almost identical for both donors we 
tested (Fig. 4.10B).  
 Next, we performed flow cytometry on adherent PBMCs after training and three 
days’ rest. We discovered that training with iRBCs or Hz appears to increase the relative 
proportion of CD14+ cells with the concomitant decrease in the relative proportion of 
CD3+ cells (Fig. 4.10C). To determine if the changes in relative cell number within the 
trained adherent PBMC population affected our results, we normalized the cytokine 
values determined by ELISA post-secondary TLR challenge to the CD14+CD45+:CD14-
CD45+ ratio for each training stimulus. As seen in Figure 4.10C, the results of the two 
normalization techniques were nearly identical, so we continued normalizing our results 
using the MTS assay. 
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Figure 4.10. P. falciparum training effects on cell morphology and adherent PBMC 
composition. (A) Adherent PBMCs were treated with media alone (RPMI+), iRBCs, or 
uRBCs for 24 h and then washed. After 3 d rest, cells were examined via light 
microscopy and representative images were selected. (B) Flow cytometry was performed 
on freshly isolated PBMCs and adherent PBMCs post adhesion to plastic for at least 1 h 
and 3x washed to remove non-adherent cells. Each donor is represented by a different 
color. (C) Flow cytometry were performed on adherent PBMCs treated as in (A). (D) 
ELISA values post-Pam3CSK4 challenge were normalized using MTS values, or using 
the ratio of CD14+CD45+:CD14-CD45+. Images in (A) are from one donor, (B) is from 
two donors, and (C and D) bars represent mean ± SD (C) or SEM (D) for four donors.  
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Malarial training may not depend on IL-12p40 or IFNg signaling 
As demonstrated in Figure 4.6D, IFNg was one of the cytokines highly upregulated by 
malarial training. Natural killer (NK) cells produce IFNg starting as little as 6 hours post-
iRBC stimulation in an IL-12- and IL-18-dependent manner, although this NK-dependent 
IFNg production is heterogeneous between donors (161-163). In a murine malaria model, 
malarial priming was IL-12- and IFNg-dependent (107). Interestingly, IFNg plays a 
necessary role in Candida albicans-induced trained immunity, and this IFNg-dependent 
training was blocked by pretreatment with the aIL-12p40 antibody ustekinumab (164). 
Transcription of the IL-12p40 subunit (IL12B) was slightly elevated in our NanoString 
dataset (Fig. 4.6D), and the IL-23p19 subunit (IL23A), which dimerizes with IL-12p40 to 
make a functional IL-23 molecule, was highly upregulated after malarial training. To test 
the role of these cytokines in malaria-induced trained immunity, we utilized neutralizing 
antibodies against either IFNg or IL-12p40. Treatment of adherent PBMCs with anti-
IFNg IgG during the 24 h first stimulation did not appear to inhibit iRBC- or Hz-induced 
training (Fig. 4.11A). Additionally, treatment of adherent PBMCs with anti-IL-12p40 
IgG continuously during the first stimulation, 3 d rest, and second stimulation did not 
appear to substantively inhibit malaria-induced training (Fig. 4.11B). However, these are 
only the results of two donors. Although these results may indicate that signaling via 
these cytokines was dispensable for malarial training, these experiments must be repeated 
with additional donors in order to conclude that these cytokines are not required for 
training in our model.  
		
	
	
	
90	
 
Figure 4.11. Malaria-induced training does not appear to be inhibited by co-treatment 
with anti-IFNg or anti-IL12p40 neutralizing antibodies. (A, B) TNFa and IL-6 ELISA 
measurements of supernatants from adherent PBMCs trained with iRBCs or Hz for 24 h, 
rested for 3 d, and challenged with Pam3CSK4 for 24 h. Cells were treated with control 
IgG or cytokine neutralizing antibody during the 24 h training stimulus (A) or throughout 
the entire 5 d experiment (B). Bars represent mean ± SEM for two donors (all 
comparisons to control IgG conditions and were not significant, paired t-test). 
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Differential epigenetic and metabolic regulation of malaria-induced trained immunity 
Trained immunity is believed to be the result of intracellular metabolic shifts leading to 
changes in epigenetic regulation of proinflammatory and other genetic loci [reviewed in 
(150)]. To determine the role of naturally-acquired malaria infection on epigenetic 
remodeling at proinflammatory and metabolic promoters, we performed H3K4me3 ChIP 
on monocytes isolated from Kenyan children with acute febrile malaria, the same 
children PCR negative for malarial infection 6 weeks after antimalarial treatment, and 
healthy adult North American controls (Fig. 4.12A). Increased H3K4me3 was seen at the 
TNF, IL6, MTOR, and GAPDH promoters during acute malaria compared to healthy 
controls. These increased H3K4me3 levels were largely unchanged six weeks after 
antimalarial treatment. We performed a similar experiment using our in vitro model on 
adherent PBMCs given a 24 h first stimulation and then allowed to rest for three days. 
Similar to the increased number of transcripts for TNF, PTGS2, and IL6 after both iRBC- 
and Hz-induced training (Fig. 4.6D), increased H3K4me3 was seen at the same 
promoters after iRBC (but not Hz) training as compared to RPMI+ training (Fig. 4.12B).  
We utilized the methyltransferase inhibitor MTA as well as the mTOR inhibitor 
rapamycin, which have previously been demonstrated to inhibit BCG-induced training 
(96) and C. albicans b-glucan-induced training (102), respectively, to investigate the 
importance of these mechanisms in malaria-induced training. Treatment with 1 mM MTA 
during the 24 h first stimulation had no effect on iRBC-induced training (Fig. 4.12C). 
MTA treatment appeared to inhibit Hz-induced training, although this did not achieve 
statistical significance, presumably due to the relatively small sample size. Conversely, 
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treatment with 10 nM rapamycin during the 24 h first stimulation blocked iRBC-induced 
training as measured by IL-6 protein production but had no effect on malarial training as 
measured by TNFa protein levels (Fig. 4.12D). 
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Figure 4.12. Epigenetic and metabolic regulation of malaria-induced training. (A) 
H3K4me3 ChIP was performed on monocytes isolated from Kenyan children with acute 
malarial disease (AM), the same children 6 weeks after antimalarial administration 
(6wk), or adult North American controls (NAM). Bars represent mean ± SEM for five 
(AM), three (6wk), or six (NAM) donors (*p<0.05, Kruskal-Wallis test). (B) H3K4me3 
ChIP was performed on adherent PBMCs trained for 24 h and rested for 3 d. Bars 
represent mean ± SEM for five (RPMI+, iRBC, uRBC) or three (Hz) donors (all 
comparisons to RPMI+ trained, *p<0.05, **p<0.01, paired t-test) (C, D) Adherent 
PBMCs were co-treated with the methyltransferase inhibitor MTA (C), the mTOR 
inhibitor rapamycin (D) or relevant vehicle controls during the 24 h training stimulation. 
Cells were rested for 3 d and challenged with Pam3CSK4 for 24 h, after which 
supernatants were removed and cytokine concentrations were assessed by ELISA. Bars 
represent mean ± SEM for three or four donors (all comparisons to no inhibitor 
conditions and were not significant unless indicated, paired t-test). 
TNF H3K4me3 IL6 H3K4me3 MTOR H3K4me3 GAPDH H3K4me3A
A
M
6w
k
N
A
M
0
5
10
15
20
%
 in
pu
t T
N
F
*
*
A
M
6w
k
N
A
M
0
1
2
3
4
5
%
 in
pu
t I
L6
p = 0.08
*
A
M
6w
k
N
A
M
0
2
4
6
8
%
 in
pu
t M
TO
R
*
p = 0.07
A
M
6w
k
N
A
M
0
2
4
6
8
10
%
 in
pu
t G
A
PD
H
*
p = 0.05
First stimulus
TNF H3K4me3
First stimulus
IL6 H3K4me3
MTOR H3K4me3 PTGS2 H3K4me3
B
R
PM
I+
5x
10
6  
iR
B
C
5x
10
6  
uR
B
C
H
z 
10
0 
µM
0.0
0.5
1.0
1.5
2.0
2.5
Fo
ld
 in
cr
ea
se
 (%
 in
pu
t T
N
F)
*
R
PM
I+
5x
10
6  
iR
B
C
5x
10
6  
uR
B
C
H
z 
10
0 
µM
0.0
0.5
1.0
1.5
2.0
Fo
ld
 in
cr
ea
se
 (%
 in
pu
t I
L6
) *
R
PM
I+
5x
10
6  
iR
B
C
5x
10
6  
uR
B
C
H
z 
10
0 
µM
0
1
2
3
4
Fo
ld
 in
cr
ea
se
 (%
 in
pu
t M
TO
R
)
**
p = 0.08
R
PM
I+
5x
10
6  
iR
B
C
5x
10
6  
uR
B
C
H
z 
10
0 
µM
0
1
2
3
4
Fo
ld
 in
cr
ea
se
 (%
 in
pu
t P
TG
S2
)
**
Pam3CSK4 (24 hr)
0
1000
2000
3000
4000
5000
TN
Fα
 (p
g/
m
L)
0 mM MTA 1 mM MTAInhibitor
Second stimulus Pam3CSK4 (24 hr)
Pam3CSK4 (24 hr)
Inhibitor
Second stimulus Pam3CSK4 (24 hr)
C
D
0
2000
4000
6000
8000
TN
Fα
 (p
g/
m
L)
0 nM rapamycin 10 nM rapamycin
0
500
1000
1500
IL
-6
 (p
g/
m
L)
0 nM rapamycin 10 nM rapamycin
*
0
1000
2000
3000
4000
IL
-6
 (p
g/
m
L)
0 mM MTA 1 mM MTA
RPMI+
106 iRBC
106 uRBC
Hz 100 µM
First stimulus
		
	
	
	
94	
Discussion 
Malaria is an extraordinarily complicated disease. Individuals from endemic regions of 
the world have a clinical syndrome that is influenced by age and previous exposures. 
Young children who have little or no immunity to malaria are at highest risk for acute 
febrile disease that may be complicated by cerebral disease or other severe sequelae (13). 
This corresponds with our findings that Kenyan children have increased H3K4me3 at 
promoters relevant to inflammation and immunometabolism both during acute malaria 
and 6 weeks post-curative therapy as compared to healthy North American adult controls. 
Given that monocyte H3K4me3 levels are higher in adults than neonates at both 
proinflammatory and metabolic promoters (165), we expect monocytes from healthy 
adults to have higher baseline H3K4me3 levels than monocytes from healthy children. 
These data further support our hypothesis that malarial infection serves as a robust 
priming and training stimulus, and these children are most likely to hyperrespond to 
infection in ways that might be predicted based on the in vitro responses we have 
described above.  
Older children and adults from endemic areas are likely to have experienced 
multiple episodes of malaria within their lifetime. These individuals will often have 
detectable parasitemia but no fever or other symptoms of disease (152). While the level 
of parasitemia in these asymptomatic malaria cases might be quite low (presumably due 
to acquired immunity), it is not uncommon for individuals to have levels of parasites in 
the blood that would require urgent treatment in the immunologically naïve. It is our 
hypothesis that the differences in outcome in disease between young individuals or 
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immunologically mature individuals who become infected for the first time later in life 
(e.g., travelers) compared to multiply infected individuals, are to some extent due to 
epigenetic changes at proinflammatory and immunometabolic promoters.  
In this work, we demonstrated that the malaria parasite and its crystal Hz can 
induce trained immunity as measured by proinflammatory gene expression after a 
secondary TLR ligand challenge. Although these two stimuli have similar effects on the 
inflammatory transcriptome post-Pam3CSK4 challenge, the differential regulation of 
iRBC- and Hz-induced training by known trained immunity inhibitors and differing 
levels of H3K4me3 at immunometabolic promoters indicate potentially divergent training 
mechanisms for the two stimuli. One potential explanation for this divergence is that the 
malaria parasite contains multiple additional ligands with innate immune stimulatory 
capacity. P. falciparum RNA is known to stimulate TLR7 (88), while GPI anchors in the 
parasite cell membrane can stimulate TLR2 (46). Although these TLRs utilize the same 
signaling cascades and transcription factors as the receptors stimulated by Hz, the balance 
in signaling between the cascades may be sufficiently different to explain these 
differences. For example, IRF3 and NFKB1, but not IRF7, transcript levels are 
downregulated by malaria training (data not shown).  
Rapamycin treatment only inhibited training as measured by IL-6 and not TNFa, 
which differs from previous studies on other training stimuli (102, 103). Given that the 
TNF and IL6 loci have different initiation kinetics and epigenetic requirements for 
transcription (166), this discrepancy in rapamycin inhibition is not completely surprising, 
but this finding, along with the apparent dispensability of IFNg signaling for malaria 
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training, provides further evidence that both malaria parasites and Hz induce innate 
immune training by mechanisms that differ from those described to date. Any hope for 
immunomodulation of malaria, either for the purposes of improving outcome in the 
critically ill or enhancing acquired immunity to the disease by immunization, requires a 
more thorough understanding of the basic pathogenesis of the disease. The methods for 
acquiring this understanding are at hand, and hence one can anticipate an era of improved 
approaches to reduce the morbidity and mortality of malaria.     
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Chapter V: Discussion 
The work described in this dissertation attempted to answer two outstanding questions in 
the subfield of innate immune recognition of malaria: 
1. What is mechanism by which monocytes and macrophages recognize P. 
falciparum genomic DNA in the cytosol? 
2. Does stimulation of monocytes and macrophages with P. falciparum 
induce innate immune memory? 
The experiments described in Chapter III of this dissertation demonstrate that the 
cytosolic DNA receptor cGAS is required for detection of P. falciparum gDNA in the 
cytosol of both human and mouse cells, and that the resulting production of 2’3’-cGAMP 
activates STING, leading to the phosphorylation of IRF3 and the transcription and 
translation of IFN-I. In Chapter IV of this dissertation, we demonstrated that stimulation 
of adherent PBMCs with P. falciparum iRBCs and Hz induces these cells to 
hyperrespond to a secondary TLR ligand challenge. We showed that this increased 
proinflammatory response to secondary TLR challenge included the increased production 
of proinflammatory cytokines and depressed production of an anti-inflammatory 
cytokine. We also demonstrated that training with malarial ligands induced widespread 
changes to the proinflammatory transcriptome after Pam3CSK4 second stimulus, and that 
these changes in transcription correlated with increased H3K4me3 marks at promoters of 
genes previously implicated in innate immune memory. We showed that these marks 
were also seen in Kenyan children naturally infected with malaria, and we generated 
preliminary data that began to tease apart the mechanism of this trained immunity. In the 
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rest of this discussion, I will examine each of these findings in more depth, draw 
conclusions about what they mean for the role of innate immunity in malaria sensing and 
pathogenesis, and indicate experiments that could strengthen these conclusions and move 
the projects in future directions. 
 
The DNA receptor cGAS recognizes P. falciparum genomic DNA in the cytosol of 
monocytes and macrophages 
Major results and conclusions 
Plasmodial DNA has been recognized as an important PAMP for quite some time. Our 
group and others have demonstrated that Plasmodium DNA is sensed by TLR9 through 
delivery to the endosome by Hz (49, 50, 53). This DNA is complexed with malarial 
histones in the form of parasite chromatin (51, 52). Patients with febrile P. falciparum or 
P. vivax have increased levels of circulating immune complexes (ICs) containing parasite 
gDNA, and these ICs stimulate human monocytes to produce TNFa and other 
proinflammatory cytokines along with increased transcription of other NF-kB-dependent 
genes (119). Additionally, Hz is able to cause loss of phagolysosomal integrity, which 
allows DNA to escape into the cytosol, where it can be detected by the cytosolic DNA-
sensing inflammasome protein AIM2 (53). Activated AIM2 inflammasomes, which are 
important for cleavage of pro-IL-1b into its active form, can also been seen in monocytes 
taken from patients with febrile P. vivax infection (119).  
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 After escape from the phagolysosome, cytosolic gDNA can also trigger the 
production of IFN-I, and our group showed that this production of IFN-I by human 
PBMCs, HEK293, and THP-1 monocytes and mouse splenocytes and BMDMs was 
largely due to the recognition of AT-rich stem-loop structures in P. falciparum gDNA 
(55).  In Figure 3.1, we demonstrate that purified human CD14+ monocytes produce IFN-
I in after stimulation with P. falciparum iRBCs or transfection with gDNA, Hz, and AT-
rich DNA motifs, and in Figure 3.2, we show that IFN-I induction by Hz is abrogated by 
pretreatment of Hz with DNase.  
In our previous work, BMDMs from various genetic knockouts or were used to 
demonstrate that this recognition of gDNA and the stem-loop motifs and the resulting 
IFN-I production required the adaptor protein STING, the kinase TBK1, and the 
transcription factors IRF3 and IRF7; however, further use of KO BMDMs and siRNA 
silencing of genes in human HEK293 demonstrated that this IFN-I production did not 
require the DNA sensors TLR9, RNA polymerase III, DAI, or p204 (55). Other potential 
DNA sensors that were not specifically evaluated in this earlier work include DDX41 
(167), IFI16 (40), and cGAS (42, 43). Interestingly, all three of these cytosolic DNA 
sensors signal through STING, making them plausible receptors for P. falciparum gDNA 
in our model. In Figures 3.3 and 3.4, we conclusively show that cGAS is required for 
IFN-I production by P. falciparum gDNA. THP-1 human monocytes deficient in cGAS 
were not able to phosphorylate IRF3 or transcribe IFNB in response to transfection of P. 
falciparum gDNA or Hz. We also found that IFI16-deficient THP-1 human monocytes 
had no defect in their ability to recognize P. falciparum gDNA as measured by IFNB 
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transcription (Fig. 3.3). The role of IFI16 in cytosolic DNA recognition remains 
controversial. One recent study demonstrated that IFI16 has was required for cGAS-
dependent IFN-I production after stimulation of THP-1 cells with dsDNA or viral ligands 
(168), while another study demonstrated that genetic deficiency of all 13 ALRs, including 
the mouse IFI16 ortholog p204, did not significantly affect IFN-I production induced by 
cytosolic DNA (169). In Figure 3.4, we demonstrate that cGAS is essential for production 
of IFNb protein after transfection of AT-rich ODNs or P. falciparum gDNA into mouse 
BMDMs. In our previous work, we showed that knockdown of the mouse ortholog of 
IFI16, p204, did not inhibit IFNb in response to transfection of AT-rich ODNs (55), and 
we found similar results with p204-/- BMDMs (data not shown). Therefore, we conclude 
that IFI16/p204 is not required for IFN-I production in response to Plasmodial DNA 
ligands, but cGAS is absolutely required. Finally, in Figure 5 we demonstrated that 
transfection of THP-1 cells or MDMs with P. falciparum gDNA induces the production 
of 2’3’-cGAMP, which has previously been described as the second messenger produced 
by cGAS that activates STING (44, 45). 
Given the wealth of recent studies demonstrating the importance of cGAS in the 
immune response against a variety of pathogens, including HIV (144), herpes simples 
virus (HSV) (42), cytomegalovirus (CMV) (142), Listeria monocytogenes (146), 
Neisseria gonorrhea (122), Mycobacterium tuberculosis (170), and Staphylococcus 
aureus (171), it is perhaps not surprising that cGAS also recognizes P. falciparum gDNA. 
cGAS was originally described as a sensor that recognized dsDNA in a length-dependent, 
sequence-independent manner. In the original description of cytosolic DNA sensing by 
		
	
	
	
101	
Stetson and Medzhitov, they showed that 45 base pair (bp) double-stranded interferon-
stimulatory DNA (ISD) induced a robust IFN-I response in mouse primary cells, but this 
IFN-I response was not seen to dsDNA sequences shorter than 25 bp (172) Other groups 
demonstrated IFN-I production by mouse and human cells after dsDNA sequences were 
delivered to the cytosol in a manner dependent on the dsDNA length, with the absolute 
minimum length required for induction of IFN-I production in human cells being between 
20-40 bp (40, 173). Therefore, it is surprising that cGAS is required for recognition of the 
AT5 ODN, which is a mere 20 nucleotides long and single-stranded (55). Although the 
stem-loop structure of AT5 is required for its ability to induce IFN-I, the predicted 
double-stranded stem is only 4 bp long (55).  
 A recent paper in Nature Immunology may be able to explain the immunogenicity 
of the AT5 ODN. Herzner and colleagues demonstrated that step-loop DNA structures 
formed from the HIV-1 genome reverse-transcribed into ssDNA can activate cGAS 
(174). As they evaluated the mechanism by which these step-loop structures activated 
IFN-I production, they discovered that short dsDNA segments—as short as 12 bp—could 
induce IFN-I production when transfected into human PBMCs if the segments had three 
unpaired guanine residues adjoining the dsDNA segment in what the authors describe as 
Y-form short DNA (YSD)(174). As with AT5 ODN, induction of IFN-I production by 
YSD is dependent on cGAS/STING and is secondary to 2’3’-cGAMP synthesis; 
additionally, they used biotin-tagged YSD to demonstrate that cGAS bound to YSD but 
not to dsDNA of the same length (174). Although the loop formed by the putative 
secondary structure of AT5 ODN does not contain any guanine residues, the Y formed on 
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the other end of the 4 bp dsDNA segment contained three guanines on one end and two 
guanines on the other end (55). Additionally, lengthening the dsDNA segment of the 
YSD increased IFN-I production until the segment was 20 bp long, after which IFN-I 
production leveled off (174). In our data, we show that AT5 3x (a 60mer repeating the 
AT5 ODN sequence three times) induces increased IFNB transcription compared to AT5 
in THP-1 cells, and this IFNB transcription is completely abrogated in cGAS-deficient 
THP-1 cells (Fig. 3.3C). This could be due to an increased dsDNA length or merely 
having three of the same Y-form structures connected in the same ODN. In either case, 
we tentatively conclude that cGAS is able to induce IFN-I production through the 
recognition of AT5 ODN. 
 
Additional experiments and future directions 
As stated in the title of this section of the discussion, we conclude that cGAS is the 
cytosolic receptor for P. falciparum gDNA and that cGAS/2’3’-cGAMP/STING 
signaling is required for IFN-I production in response to stimulation with cytosolic 
Plasmodial DNA. We also show provide strong evidence supporting cGAS as the sensor 
for AT-rich stem-loop ODNs like AT5; however, we could support this conclusion by 
creating a biotinylated version of AT5 and using a pull-down assay to determine if cGAS 
is able to bind AT5. We could also utilize biotinylated AT5 3x and dsAT5 4x to 
determine if the increased IFN-I transcription after transfection of these sequences was 
due to an enhanced ability to bind cGAS. To further demonstrate that AT5 and its 
derivatives activate cGAS to produce 2’3’-cGAMP, we could repeat the LC-MS/MS 
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experiment described in Figure 3.5 on supernatants from THP-1 cells transfected with 
AT5. 
 In this work, we demonstrated that IFN-I production by human and mouse 
monocytes and macrophages in response to Plasmodium DNA ligands required cGAS. 
Additionally, we showed that transfection of Hz induced IFN-I in a dose-dependent 
manner. This IFN-I production also required cGAS and was completely abrogated by 
DNAse treatment, indicating that the role of Hz in this IFN-I induction was really that of 
a DNA shuttle (53). What this work did not show was a definitive requirement for cGAS 
in iRBC-driven IFN-I production. We stimulated cGAS-competent and cGAS deficient 
THP-1 cells with iRBCs, but were unable to measure IFNB transcription (data not 
shown). Even though we use PMA to differentiate the THP-1 cells into macrophage-like 
cells, we did not see robust phagocytosis of iRBCs or Hz (J.E.S., unpublished 
observation). Presumably, this inability to phagocytose malaria or its products prevented 
delivery of P. falciparum gDNA to the cytosol for recognition by cGAS—hence the 
requirement for transfection of Hz. 
 As described in Figure 4.1A, stimulation of CD14+ monocytes with iRBCs 
induces IFNB transcription; however, as elucidated in the introduction, P. falciparum can 
induce IFN-I expression through multiple PAMP-PRR interactions. There are a few tools 
that could be used to illuminate the role of cGAS in IFN-I production in response to 
iRBC stimulation. Future experiments could use genetic knockouts of other cell lines, 
such as the BLaER1 cells described in Figure 4.7. CRISPR-Cas9 technology has already 
been utilized to make multiple knockout lines from these cells (124). Mouse BMDMs 
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could also be used, but they produce little to no IFN-I after stimulation with P. 
falciparum iRBCs (data not shown). If primary cells are preferred, siRNA knockdown of 
cGAS in human CD14+ monocytes could be attempted. Although transfection of human 
primary phagocytic cells has traditionally been difficult, a protocol purporting efficient 
siRNA gene knockdown in monocytes was recently published (175). Small molecule 
inhibition of cGAS would be another possible way to demonstrate the role of cGAS in 
iRBC sensing. Interestingly, multiple antimalarial drugs, including chloroquine, 
hydroxychloroquine, and primiquine, block DNA binding to cGAS and inhibit IFNB 
expression in THP-1 cells transfected with DNA (176); however, an antimalarial drug 
would not be the best choice to investigate cGAS activation by malaria parasites. In fact, 
Shizuo Akira’s group demonstrated over a decade ago that chloroquine blocked Hz-
mediated cytokine production (50). An indirect method for demonstrating the role of 
cGAS in recognizing P. falciparum iRBC would be to repeat the experiment described in 
Figure 3.5 by stimulating CD14+ monocytes with iRBCs and utilizing LC-MS/MS to 
look for production of 2’3’-cGAMP. 
 The next question that needs to be addressed is the role of the cGAS/2’3’c-
GAMP/STING in malaria immunity and disease. Our group has previously shown that 
PBMCs and neutrophils taken from patients naturally infected with malaria show 
increased expression of ISGs, indicating that production of IFN-I is involved in the acute 
response to malaria (55, 134). Given our group’s access to clinical malaria patients in 
Columbia and Brazil, we are currently collecting serum samples from patients for future 
LC-MS/MS analysis to look for 2’3’-cGAMP. This would provide strong evidence for 
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cGAS activation in human disease. An alternative method for implicating cGAS in 
malarial disease in vivo is the use of one of the malaria mouse models. The P. chaubaudi 
model has been used to demonstrate the necessity of various cell types and PRRs for 
malaria-induced IFN-I production (87, 88), while P. yoelii N67 infection in mice induces 
cytosolic RNA sensor-dependent IFN-I production that is necessary for controlling 
parasitemia (177). As described in the introduction, IFN-I production is detected in mice 
infected with the ECM-inducing PbA species, and mice deficient in the IFN-I receptor 
are protected from ECM (85, 86). Our group has shown that TBK1- and IRF3/7-deficient 
mice are also spared from ECM lethality (55), and we hypothesize that the requirement 
for these molecules in ECM pathogenesis is due at least in part to their downstream 
activation after stimulation of the cGAS/2’3’cGAMP/STING axis in PbA infection.  
 
Stimulation of adherent PBMCs with P. falciparum parasites or Hz induces trained 
innate immunity 
Major results and conclusions 
As described in Chapter I of this dissertation, the naturally-acquired immune response to 
malaria is complex. Those most at risk for severe outcomes from malarial infection are 
individuals whose immune systems have not been exposed to the parasite—such as 
infants in endemic areas and adults from non-endemic areas—or individuals who had 
developed natural immunity to malaria while living in an endemic area, moved to a non-
endemic area for a period of years, and then are re-exposed to malarial infection. When 
the immune system encounters malarial parasites for the first time, a priming effect is 
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seen, and the immune system is hyperresponsive to a secondary challenge experienced 
during acute infection (106, 107). However, if the infection is allowed to progress and 
patients have multiple febrile paroxysms without sterilizing antimalarial treatment, their 
immune system can become hyporesponsive to subsequent innate immune challenge, as 
seen in historical studies examining the immune response to bacterial products after 
infection with malaria as treatment for neurosyphilis (115). Tolerance to malaria can also 
develop after experiencing multiple infections, as the parasite burden required to initiate 
fever increases with multiple infections (151), and many healthy individuals in endemic 
areas are infected with P. falciparum for weeks or even months with no fever or other 
symptoms (152). Given that priming and tolerance are two stages of the recently 
described model of innate immune memory (97), we hypothesized that malaria could also 
induce trained innate immunity; that is, stimulation with malaria could induce the innate 
immune system to hyperrespond to a later secondary challenge. To our knowledge, the 
results described in Chapter IV of this dissertation represent some of the first evidence in 
favor of trained innate immunity induction by P. falciparum. 
We have developed a robust, reproducible in vitro assay in which pretreatment of 
adherent human PBMCs with P. falciparum iRBCs or Hz, followed by removal of these 
ligands and a rest period, induces these cells to hyperrespond to subsequent TLR 
stimulation. In Figure 4.1, we demonstrate that adherent PBMCs taken from 
leukapheresis products and trained with P. falciparum products produced increased 
proinflammatory cytokines after three or five days’ rest to a secondary TLR stimulus. 
Overall, the effect of malarial training appeared more robust at three days’ rest, so we 
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used that time point for the rest of our experiments. In Figure 4.2, we showed that 
malaria-induced training appeared to depend on the presence of multiple cell types, as 
monocytes alone did not display trained immunity; in fact, iRBC primary stimulation 
appeared to induce tolerance to subsequent LPS stimulation (Fig. 4.2D).  
Given the drawbacks of using leukapheresis products, we shifted our model to 
using adherent PBMCs from blood freshly drawn in-house from healthy human donors. 
We demonstrated that malaria-induced training was reproducibly seen in adherent 
PBMCs from an individual donor drawn multiple times over a thirteen-month period 
(Fig. 4.3). We then expanded our donor pool and demonstrated that training with P. 
falciparum iRBCs or Hz induced increased TNFa and IL-6, but decreased IL-10 post-
Pam3CSK4 challenge (Fig. 4.4 and 4.5). This differs slightly from the original 
description of trained immunity to Candida albicans, in which pretreatment with C. 
albicans and secondary challenge with Pam3CSK4 induced increased TNFa and IL-6, 
but had no effect on IL-10, as compared to control-trained cells (95). Given that IL-10 is 
produced at extremely high levels during malaria infection, especially severe malaria 
(178), while IL-10 is decreased during in vitro malaria-induced priming (106), I conclude 
that this decreased production of IL-10 after malaria training and TLR2 challenge 
represents immunomodulation by malarial ligands and not merely a synergistic effect 
between malaria ligands and Pam3CSK4 stimulation. We also demonstrated that malarial 
training induces wide-ranging changes to the inflammatory transcriptome post-
Pam3CSK4 challenge (Fig. 4.6). 
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In order to broaden the scope of our in vitro assay, we attempted to replicate our 
results from human adherent PBMCs with two human immortalized monocyte-like cell 
lines, BLaER1 cells (124, 159) and THP-1 cells, and two different types of mouse 
primary cells, BMDMs and non-thioglycolate-elicited PECs. Our hope was that, by 
replicating our results in a cell line or mouse primary cells, we could use CRISPR-Cas9 
or other genetic manipulation techniques to probe the PRR requirements for our training 
phenotype. We found increased production of TNFa and IL-6 after training with 106 
iRBCs and LPS challenge in BLaER1 cells (Fig. 4.7B, C), but not after challenge with 
Pam3CSK4 (Fig. 4.7D), the secondary stimulus that gave us the most robust results in the 
human adherent PBMC assay. We also failed to see training or tolerance induction in 
THP-1 cells (Fig 4.8). In mouse BMDMs, we saw significant increase in TNFa after 
training with Hz/challenge with Pam3CSK4 (Fig. 4.9A) and RANTES after training with 
iRBCs and challenge with Pam3CSK4 or LPS (Fig. 4.9B). Interestingly, RANTES was 
highly expressed in Flt3 ligand-derived dendritic cells in a TLR9-dependent manner after 
stimulation with P. falciparum gDNA delivered to the endosome by Hz (49); however, 
training with various concentrations of Hz did not induce increase RANTES expression 
post-Pam3CSK4 or LPS challenge (Fig. 4.9B). Mouse PECs, on the other hand, after 
pretreatment with PbA iRBCs for 36 hours and three days’ rest, produced significantly 
less TNFa after challenge with Pam3CSK4 and LPS as compared to control-pretreated 
cells (Fig. 4.9C).  
There are few potential explanations for these seemingly conflicting results in 
mouse primary cells of training to iRBCs in BMDMs but tolerance in PECs. First, the 
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ligand usage was slightly different: P. falciparum iRBCs and Hz were used in BMDMs, 
while PbA iRBCs were used in PECs. As mentioned earlier, PbA infection in mice is 
used in the ECM model, which attempts to mimic CM in P. falciparum infection, but the 
diseases are not identical. One of the major arguments over the ECM model and its 
relevance to human disease is the role of the immune system in pathogenesis—it is 
absolutely required in PbA ECM, but its role is disputed in human CM [see Chapter I and  
(179, 180)]. This could indicate that PbA is more immunogenic—at least in mouse 
primary cells—than P. falciparum. Additionally, in our PEC experiment, we stimulated 
the cells with 2.4x106 PbA iRBCs for 36 hrs instead of the usual 106 P. falciparum iRBCs 
for 24 hrs. Previous work in the field of innate immune memory has shown that 
increasing the dose of a stimulus can shift its effect from training to tolerance (105, 181), 
so this could play a role. Finally, BMDMs and PECs have different activation levels at 
baseline. PECs express significantly higher levels of Tnf, Il6, Ptgs2, Ifnb1, and Il12a—all 
genes previously discussed in this dissertation to be involved in malaria recognition 
and/or innate immune memory—than BMDMs before any stimulation (182). Increased 
expression of proinflammatory genes at baseline could cause PECs stimulated with PbA 
iRBCs to become activated to the point of tolerance induction rather than training. 
Many early studies demonstrating trained immunity also utilized adherent PBMCs 
(95, 96, 105). We presumed that the adherent PBMCs would be primarily monocytes, as 
purities of ~90% monocytes from isolation through adherence have been reported (121). 
Surprisingly, we noticed almost no enrichment for monocytes after allowing the PBMCs 
to adhere in 96-well round-bottom plates for at least 1 h (Fig. 4.10B). As mentioned 
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previously, we noticed differences in cell numbers after training with different ligands. 
After looking more closely at the cells, we also noticed training ligand-dependent 
differences in cell morphology (Fig. 4.10A). To determine if there were differences in 
cell type proportions after training, we performed flow cytometric analysis on the 
remaining adherent PBMCs after the first stimulus and three-day rest. To our surprise, 
adherent PBMCs trained with iRBCs or Hz had increased numbers of CD14+ monocytes 
compared to control-trained populations (Fig. 4.10C). Throughout our experiments, we 
utilized a MTS assay to normalize all cytokine values to cell number (see Chapter II). For 
all experiments in which we evaluated the trained cell population using flow and 
performed secondary stimulation, we normalized cytokine production to the ratio of 
CD14+CD45+ cells: CD14-CD45+ cells. The results of this normalization technique were 
almost identical to the results for the MTS normalization technique (Fig. 4.10D); 
therefore, it appears that the differences in cell numbers after training of adherent PBMCs 
is largely due to an overrepresentation of CD14+ macrophages, and that even after 
normalizing for cell number—which appears to be due primarily to differences in 
macrophage cell number—we still see significant differences in cytokine production 
between malaria-trained adherent PBMCs and control-trained adherent PBMCs. 
Given that there is a significant population of non-monocyte adherent PBMCs 
present during training (Fig. 4.10B) and malaria-induced training was not seen in 
negatively-selected monocytes (Fig. 4.2), we hypothesized that the requirement for non-
monocyte cells was due to IFNg production by NK cells or T cells (164). Surprisingly, 
there appeared to be no difference in training when the adherent PBMCs were treated 
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with neutralizing antibodies against IFNg or the IL-12p40 subunit; however, these 
experiments were only performed on adherent PBMCs from two donors (Fig. 4.11). 
These results will be analyzed in further detail in the next section of this discussion. 
The current paradigm for trained immunity holds that this phenomenon is at least 
in part epigenetically mediated. Concurrent with this model, we found increased 
H3K4me3 at important proinflammatory and metabolic promoters in our in vitro trained 
adherent PBMCs (Fig 4.12B). We also found increased H3K4me3 at these promoters in 
monocytes isolated from Kenyan children naturally infected with malaria and 6 weeks 
after sterilizing antimalarial treatment as compared to North American adult controls 
(Fig. 4.12B). The fact that these differences were seen in monocytes in infected Kenyan 
children lends support to the conclusions that a) the training phenotype seen in our in 
vitro model is due at least in part to monocytes, and b) that this training phenotype may 
be seen in naturally-acquired malarial disease. Finally, we found that co-treatment of 
adherent PBMCs with the methyltransferase inhibitor MTA appeared to abrogate Hz-
induced training while not affecting iRBC-induced training (Fig 4.12C), while use of 
rapamycin as an inhibitor appeared not to have an effect on malaria-induced training as 
measured by TNFa, but significantly inhibited iRBC-induced training when measuring 
IL-6 (Fig. 4.12D). If these results are corroborated through further experimentation (see 
below), they could indicate that malaria induces training of the innate immune system 
through a novel mechanism. 
 
		
	
	
	
112	
Additional experiments and future directions 
One of the most obvious actions we can take to strengthen the conclusions made in this 
work is to increase the numbers of donors tested, especially for some of the mechanistic 
experiments where large changes were seen, but the number of donors tested was too 
small to achieve statistical significance. I include the data showing differences between 
adherent PBMCs and monocytes (Fig 4.2), and the rapamycin and MTA inhibition 
studies in this group (Fig. 4.12C and D). However, I believe those trends are large 
enough that they will become statistically significant after increasing the number of 
donors tested.  
The biggest caveat to the work presented in Chapter IV is that the trained 
immunity assay was primarily performed using adherent PBMCs. For this to be 
considered innate immune memory, we must demonstrate that the phenotype is due to 
innate immune cells. It is completely reasonable—and perhaps advantageous—for the 
training stimulus to occur in a heterogeneous population containing both innate and 
adaptive cells; after all, very few humans contracting malaria have completely deficient 
adaptive immune systems. However, our conclusions would be strengthened if we could 
more definitively show that the hyperresponsiveness to secondary challenge in our assay 
is due to an innate immune response, presumably increased cytokine production by the 
CD14+ monocyte/macrophage compartment. Based on the fact that increased levels of 
proinflammatory cytokines are seen as a result of malarial training even after normalizing 
for cell number and the ratio of CD14+CD45+ cells/CD14-CD45+ cells present at the time 
of secondary stimulation (Fig 4.10D), I conclude that the phenotype seen in this assay 
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represents trained innate immunity. To confirm that the increased proinflammatory 
cytokine production after challenge is actually due to hyperresponsiveness of the innate 
compartment of the adherent PBMCs, further experiments are warranted. 
 Based on our hypothesis of epigenetic modifications at proinflammatory 
promoters, I expect that each trained macrophage should produce increased amounts of 
TNFa and IL-6 after secondary Pam3CSK4 challenge. This could be demonstrated by 
performing intracellular cytokine staining using florescent antibodies against these 
cytokines. We attempted this experiment, but had issues with the autofluorescence of 
phagocytosed Hz in the trained cells (data not shown). We are currently troubleshooting 
ways to get around this autofluorescence, but if we are unable to do so, another option 
would be to perform the training stimulation and three-day rest with adherent PBMCs 
and then separate the CD14+ myeloid cells from the rest of the adherent PBMCs just 
before secondary challenge. Magnetic separation would be one way to do this, but it 
would have to utilize positive selection, as many of the trained macrophages still contain 
Hz in their lysosomes and/or cytoplasm and would thus be retained during magnetic 
separation (data not shown). In our trained immunity experiments on monocytes, we 
utilized negative selection in an effort to disturb the cells as little as possible before 
training; however, this positive selection would occur directly before secondary 
stimulation, so any inadvertent stimulation or physical disturbance of the cells as a result 
of the antibodies utilized for positive selection would have little time to affect the assay. 
Another major caveat to our work related to the use of adherent PBMCs is that we 
did not control for potential changes in adherent PBMC composition when looking at 
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mRNA expression or epigenetic changes. As stated previously, it appears that our 
utilization of a MTS assay for cytokine normalization controls for changes in relative 
CD14+ cell numbers within the adherent PBMC population, but we do not have a similar 
compensation mechanism for our other data. The mRNA expression data and ChIP data 
are normalized to cell number by using housekeeping genes and percent input, 
respectively, but the differences seen between training stimuli could conceivably be due 
merely to changes in the adherent PBMC composition, such as increased relative 
numbers of macrophages. However, the fact that increased H3K4me3 at proinflammatory 
promoters is seen in monocytes isolated from children with uncomplicated malaria and 6 
weeks after sterilizing treatment (Fig. 4.12A) support our conclusion that the increase in 
H3K4me3 seen in our in vitro model is at least partially monocyte-dependent. Again 
though, the H3K4me3 levels in monocytes from Kenyan pediatric malaria patients were 
compared to healthy North American adults. Although previous studies indicate that 
H3K4me3 levels, particularly at proinflammatory promoters, are positively correlated 
with age (165), it is possible that monocytes from Kenyan children have higher baseline 
H3K4me3 levels than those from North American adults. An optimal control would be 
age-matched, malaria-naïve Kenyan children from the same community, but the 
prevalence of malaria in Kisumu Country drastically decreases the odds of finding such 
controls (183). 
The above paragraphs focus on experimental methodologies to evaluate the 
importance of the CD14+ monocyte/macrophage compartment to the training phenotype 
seen in this work. As shown in Figure 4.2, stimulating negatively selected monocytes 
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with malarial ligands does not appear to induce increased cytokine production after 
secondary TLR stimulation; therefore, another related question is what cell type(s) is(are) 
required during the training stimulation. To answer this question, we can utilize magnetic 
separation to selectively deplete other cell types, such as CD3+, CD19+, or CD56+ cells, 
from PBMCs before adherence and then perform the trained immunity assay. Once we 
find that cells expressing one or more of these markers are required for trained immunity, 
we can then use additional cell markers, such as ab vs gd T-cell receptors (TCRs) to 
determine the exact cell population(s) required for the malaria-induced training 
phenotype. 
If by using selective depletion of cell types from the parent PBMC population we 
can determine which cell types are required for malaria-induced trained immunity, we 
can then use transwell assays to determine if direct cell-cell contact between different cell 
types is required for the training phenotype. There is already evidence for direct contact 
as a requirement for cytokine production in malaria stimulation experiments. For 
example, an early study examining the production of TNFa by PBMCs in response to 24 
h stimulation with P. falciparum iRBCs demonstrated that PBMCs depleted of CD3+ 
cells produced lower levels of TNFa than the parent PBMC population (184), indicating 
synergy between CD3+ and CD14+ cells in producing TNFa. Experiments from Eleanor 
Riley’s group revealed that robust IFNg production by NK cells requires direct contact 
with other cell types present in PBMCs, presumably cells from the myeloid compartment 
(185).  
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 Another possibility is that direct contact between different cell populations is not 
required, but that a soluble factor from a non-macrophage cell is required for trained 
immunity. The most obvious candidate for this soluble factor is a cytokine. As described 
earlier, trained immunity to Candida albicans required IFNg from T cells or NK cells 
(164). In Figure 4.11, we presented data indicating that IFNg-dependent signaling during 
the 24 h training period may not be required for malaria-induced trained immunity. In 
addition to repeating the neutralization antibody experiments in Figure 4.11, it would also 
strengthen our conclusion if we confirmed that the concentration and duration of 
neutralization antibody treatment were sufficient to truly neutralize the cytokine. We used 
similar concentrations to those that were recommended by the manufacturer or published 
previously (164), but we did not confirm complete cytokine neutralization. Neutralization 
of IL-12 could be evaluated by performing an IFNg ELISA on the cell supernatants after 
anti-IL-12p40 antibody treatment. To confirm neutralization of all IFNg, we could utilize 
a MHC II expression assay in human COLO-205 cells (186). 
Multiple cell types have been demonstrated to produce IFNg within the first 24 
hrs of exposure to malaria. As mentioned in Chapter IV, IFNg is produced by NK cells in 
as little as 6 hrs after initiating exposure to iRBCs, and that this IFNg production is IL-12 
and IL-18 dependent, but that this IL-18 production by macrophages is TLR2-
independent (187).  Another group demonstrated that gd T cells produce IFNg after 18 h 
of iRBC stimulation (188), and this production of IFNg by gd T cells is optimally induced 
by live iRBCs rather than killed iRBCs (189). When gd T cells are depleted from PBMCs 
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before stimulation with iRBCs for 24 hrs, the majority of IFNg production is lost, 
indicating that gd T cells are the primary IFNg-producing cells at this time point (190). 
Interestingly, both the number of Vd2+ gd T cells and the percentage of these cells 
producing TNFa and IFNg decrease as an individual experiences increased malarial 
infections, leading to speculation that this phenomenon may play a role in malarial 
tolerance (191). An early study demonstrated that PBMCs stimulated with iRBCs 
produced large amounts of IFNg but low levels of IL-12, and that transcript levels of 
IFNG remained high even after 48 hrs of stimulation (184). This raises the question of 
whether we used sufficient concentrations of neutralizing anti-IFNg antibody or if the co-
administration only during the 24 h first stimulation—and not throughout the entire 
duration of the assay—was sufficient to block all IFNg, as the adherent PBMCs could be 
continuing to produce IFNg even after extracellular iRBCs or Hz are removed by 
washing.  
The previous pages in this section have discussed technical caveats to our 
findings: increasing sample size, confirming that the training phenotype is due to innate 
immune cells, and determining what other cell types/interactions are required for the 
training phenotype. However, the more philosophical caveat that can be made about this 
work concerns the definition of memory: does this assay, in which the majority of the 
training phenotype is seen with a three-day rest, really constitute memory?  
In two of the early studies to demonstrate trained immunity in human adherent 
PBMCs, the rest period between the training stimulus and the secondary challenge was 
six days (95, 96). For one of the training stimuli utilized in these papers, the BCG 
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vaccine, it was shown that the training effects of BCG in vaccination of human subjects 
could last up to one year after vaccination (192). Indeed, in the 2011 Cell, Host, and 
Microbe paper in which they coin the phrase “trained immunity”, Mihai Netea and 
colleagues point to epidemiological studies demonstrating the protective effect of BCG 
vaccination on all-cause mortality as in vivo evidence for trained immunity (97). In a later 
study, Netea and colleagues explore the effect of rest duration on trained immunity in 
vitro for a variety of training stimuli (193). In general, they find that rest periods of one, 
three, or six days have little effect on the training phenotype; however, for 24 hrs of BCG 
training and a secondary challenge of Pam3CSK4, there is significantly more IL-6 
production compared to control-trained cells when the rest period is three days rather 
than 6 days (193). This finding mirrors our results using 105 iRBCs as a training stimulus: 
significantly increased IL-6 was seen after a three-day rest and Pam3CSK4 challenge, but 
not after five-day rest and Pam3CSK4 challenge (Fig. 4.1B). Also, our data using 
monocytes from Kenyan pediatric malaria patients indicate that increased H3K4me3 seen 
at proinflammatory promoters during acute malarial infection is also seen 6 weeks after 
initiation of curative treatment (Fig. 4.12A). These results support the conclusion that 
malarial trained immunity is a form of innate immune memory. 
To summarize, in this work we demonstrate that cGAS is the cytosolic DNA 
sensor that recognizes P. falciparum DNA ligands. We also demonstrate that P. 
falciparum can induce trained innate immunity in an in vitro model and provide 
correlative evidence that this training phenotype is also seen during naturally acquired 
malarial infection. Given that malaria-induced IFN-I production has been demonstrated 
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to have immunomodulatory effects on both innate and adaptive immune cells (82, 83, 86, 
134, 194, 195) it is tempting to speculate that IFN-I production by cGAS-dependent 
recognition of P. falciparum cytosolic DNA ligands could play a role in the trained innate 
immunity induced by malarial infection. Preliminary experiments utilizing P. falciparum 
gDNA and AT-rich ODN as priming stimuli are currently underway. As is often the case 
in scientific inquiry, more studies are needed. 
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